

Diabetes

Care

NOVEMBER 1992

Original Articles

- 1449** *Hemophilus influenza* infection of an implantable insulin-pump pocket R.P. Levy, M.D. Borchelt, R.M. Kremer, S.J. Francis, C.A. O'Connor
- 1451** Microalbuminuria immunoassay based on antibodies covalently conjugated to Eupergit C-coated beads B. Solomon, G. Fleminger, F. Schwartz, R. Doolman, B.-A. Sela
- 1455** Family history of diabetes in relation to different types of obesity and change of obesity during 12-yr period: results from prospective population study of women in Göteborg, Sweden L. Lapidus, C. Bengtsson, L. Lissner, U. Smith
- 1459** Quality of life of pancreatic transplant recipients F.K. Milde, L.K. Hart, P.S. Zehr
- 1464** Epidemiology of insulin-using commercial motor vehicle drivers: major variability of state licensing requirements in the U.S. I.F. Gower, T.J. Songer, H. Hylton, N.L. Thomas, J.-M. Ekoe, L.B. Lave, R.E. LaPorte
- 1468** Metabolic effects of dietary fructose in diabetic subjects J.P. Bantle, J.E. Swanson, W. Thomas, D.C. Laine
- 1477** Dropout and relapse during diabetes care A.L. Graber, P. Davidson, A.W. Brown, J.R. McRae, K. Wooldridge
- 1484** Relationship between adsorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry J.P. Vora, A. Burch, J.R. Peters, D.R. Owens
- 1494** A multisite physician's office laboratory evaluation of an immunological method for the measurement of HbA_{1c} R. Guthrie, R. Hellman, C. Kilo, C.E. Hiar, L.E. Crowley, B. Childs, R. Fisher, M.B. Pinson, A. Suttner, C. Vittori
- 1499** Short-term effects of alterations in dietary fat on metabolic control in IDDM P. Ireland, K. O'Dea, A. Nankervis
- 1505** Nitrate levels in community drinking waters and risk of IDDM: an ecological analysis J.N. Kostraba, E.C. Gay, M. Rewers, R.F. Hamman
- 1509** Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 yr D.A. Malerbi, L.J. Franco, The Brazilian Cooperative Group on the Study of Diabetes Prevalence
- 1517** Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance H. Yoneda, H. Ikegami, Y. Yamamoto, E. Yamato, T. Cha, Y. Kawaguchi, Y. Tahara, T. Ogihara
- 1522** Residual left ventricular pump function after acute myocardial infarction in NIDDM patients T. Iwasaka, N. Takahashi, S. Nakamura, T. Sugiura, N. Tarumi, Y. Kimura, N. Okubo, H. Taniguchi, Y. Matsui, M. Inada

1824 Letters

- Quality control measures in glucose monitoring
Acute onset of seeming IDDM in an AIDS patient
Intracellular magnesium deficiency
Treatment of malignant otitis externa in a younger diabetes patient
Criteria critique
Reply to Dr. O'Sullivan

1828 ADA News and Meetings

1832 Système International (SI) Units Table

Abstract Form for 53rd Scientific Sessions

► Table of contents continued

ames

HbA_{1c}

*Introducing the DCA 2000™ Analyzer
that makes easy HbA_{1c} testing possible in your office*



Easy procedure

Simple steps enable in-office convenience in hemoglobin A_{1c} testing.

- Test requires only 1 μ L of whole blood collected in a capillary holder.
- Capillary holder is inserted into a reagent cartridge and placed into analyzer.
- No manual calculations... results are automatically displayed.

Easy to interpret

High-level accuracy achieved in clinical studies from multiple sites ensures quality performance.

- Correlation of 0.99 indicates excellent agreement with HPLC methods.
- Coefficients of variation less than 5% show the analyzer's excellent precision.

Easy patient management

With 9-minute HbA_{1c} results, consultation with patients can occur during the office visit.

- Eliminate days of waiting for send-out HbA_{1c} results.
- No telephone call-backs... patients can be immediately advised of needed adjustments in their blood glucose control.
- The DCA 2000 Analyzer makes it easy to follow the clinical guidelines for regular HbA_{1c} testing.*

*Clinical guidelines: Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 12:365-68, 1989.

ASAP



HbA_{1c} made easy with the
DCA 2000™ Analyzer

For more information about the DCA 2000 Analyzer, contact
your Miles representative or call toll-free, 1-800-445-5901.

The DCA 2000™ Analyzer



Diagnostics Division
Miles Inc.
Tarrytown, NY 10591

Diabetes Care

American Diabetes Association Officers 1992-93

Chairman of the Board

ROSS V. HICKEY, JR.

Chairman of the Board-Elect

MICHAEL A. GREENE

President

F. XAVIER PI-SUNYER, MD

President-Elect

JAMES R. GAVIN III, MD, PHD

Senior Vice-President

PATRICIA STENGER, RN, CDE

Vice-Chairman of the Board

DOUGLAS LUND

Vice-Presidents

LINDA A. SIMINERIO, RN, MS, CDE
KATHLEEN L. WISHNER, PHD, MD

Secretary

SARA NOLEN

Treasurer

STEPHEN J. SATALINO

Office of the Executive

JOHN H. GRAHAM IV
RICHARD KAHN, PHD
CAROLINE STEVENS

Diabetes Care publishes original articles and reviews of human and clinical research intended to increase knowledge, stimulate research, and promote better management of people with diabetes mellitus. Emphasis is on human studies reporting on the pathophysiology and treatment of diabetes and its complications; genetics; epidemiology; psychosocial adaptation; education; and the development, validation, and application of accepted and new therapies. Topics covered are of interest to clinically oriented physicians, researchers, epidemiologists, psychologists, diabetes educators, and other professionals.

All manuscripts and other editorial correspondence should be sent by first class mail to Allan L. Drash, MD, Editor, *Diabetes Care*, Children's Hospital, Rangos Research Center, 3705 Fifth Avenue, Pittsburgh, PA 15213. Manuscripts and correspondence regarding review articles should be sent to Ralph A. DeFronzo, MD, Review Editor, *Diabetes Care*, Department of Medicine, Division of Diabetes, UT-HSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78284.

Diabetes Care publishes only original material. When submitting a manuscript, authors must state in their transmittal letter that the material has not been previously published or is not currently being submitted to another journal.

Manuscripts should be prepared in accord with the requirements specified in the document "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," *Annals of Internal Medicine* 96: 766-71, 1982. An "Instructions for Authors" page containing specifications for manuscript preparation appears quarterly beginning with the January issue of each volume.

All material published in *Diabetes Care* is copyrighted by the American Diabetes Association, Inc. All manuscripts submitted to *Diabetes Care* must include

a transmittal letter stating the following before they will be considered for publication. "In consideration of ADA reviewing my (our) submission, the undersigned author(s) transfers, assigns, or otherwise conveys all copyright ownership to ADA in the event the work is published." Permission to reproduce copyrighted material from *Diabetes Care* will be granted for limited, noncommercial purposes. Permission requests should be addressed to the Permissions Editor, ADA, 1660 Duke St., Alexandria, VA 22314 and should be accompanied by a letter of permission from the senior author of the article.

Diabetes Care (ISSN 0149-5992) is published monthly by the American Diabetes Association, Inc., 1660 Duke Street, Alexandria, VA 22314. The annual subscription rate is \$75 for individuals in the U.S. and Canada. Professional Membership dues include \$35 designated for *Diabetes Care*. The annual rate for all foreign subscriptions, excluding Canada, is \$95. The fee for individual copies is \$8 in the U.S. and Canada and \$10 in all other countries. Second class postage paid at Alexandria, Virginia 22314, and at additional mailing offices. POSTMASTER: Send change of address to *Diabetes Care*, American Diabetes Association, Inc., P.O. Box 2055, Harlan, IA 51593-0238.

Diabetes Care is listed in Science Citation Index, Current Contents/Life Sciences, Current Contents/Clinical Medicine, SCISEARCH, ISI/BIOMED databases, and Automatic Subject Citation Alert. *Diabetes Care* is available online on BRS Colleague. For more information call 800-468-0908. It is also available in machine-readable format from University Microfilms International. *Diabetes Care* is printed on acid-free paper starting with Vol. 11(1), 1988.

© 1992 by the American Diabetes Association, Inc.

- 1527** Leukocyte scanning with ¹¹¹In is superior to magnetic resonance imaging in diagnosis of clinically unsuspected osteomyelitis in diabetic foot ulcers
L.G. Newman, J. Waller, C.J. Palestro, G. Hermann, M.J. Klein, M. Schwartz, E. Harrington, M. Harrington, S.H. Roman, A. Stagnaro-Green
- 1531** Prevalence of *Corynebacteria* in diabetic foot infections *A.N. Bessman, P.J. Geiger, H. Canawati*
- 1534** Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se *H.D. McIntyre, A. Ma, D.M. Bird, C.A. Patterson, D.P. Cameron*
- 1541** Impact of NIDDM on mortality and causes of death in Pima Indians *M.L. Sievers, R.G. Nelson, W.C. Knowler, P.H. Bennett*
- 1550** Mexiletine in the treatment of diabetic neuropathy *H. Stracke, U.E. Meyer, H.E. Schumacher, K. Federlin*
- 1556** Epidemiology of childhood type I diabetes in Sudan, 1987-1990 *A. Elamin, M.I.A. Omer, K. Zein, T. Tuvemo*
- 1560** Glycemic control and complications in type II diabetes: design of a feasibility trial *C. Abaira, N. Emanuele, J. Colwell, W. Henderson, J. Comstock, S. Levin, F. Nuttall, C. Sawin, VA CS Group (CSDM)*
- 1572** Effect of high carbohydrate intake on hyperglycemia, islet function, and plasma lipoproteins in NIDDM *A. Garg, S.M. Grundy, M. Koffler*
- 1581** Screening for microalbuminuria: a comparison of single sample methods of collection and techniques of albumin analysis *S.J. Schwab, F.L. Dunn, M.N. Feinglos*
- 1585** Contraception in women with IDDM: an epidemiological study *K. Kjær, C. Hagen, S.H. Sandø, O. Eshøj*
- 1591** Renal hemodynamics and albumin excretion rate in patients with diabetes secondary to acquired pancreatic disease *A. Tiengo, G. Briani, E. Scaldaferrì, F. Riva, E. Jori, E. Sgnaolin, R. Fenato, M. D'Ambrosio, P. Fioretto, R. Nosadini, G. Crepaldi, R. Trevisan*
- 1598** Randomized prospective double-blind trial in healing chronic diabetic foot ulcers: CT-102 activated platelet supernatant, topical versus placebo *D.L. Steed, J.B. Goslen, G.A. Holloway, J.M. Malone, T.J. Bunt, M.W. Webster*
- 1605** Prediction of infant birth weight by GDM screening tests: importance of plasma triglyceride *R.H. Knopp, M.S. Magee, C.E. Walden, B. Bonet, T.J. Benedetti*
- 1614** Early disturbances of ambulatory blood pressure load in normotensive type I diabetic patients with microalbuminuria *P.Y. Benhamou, S. Halimi, R. De Gaudemaris, R. Boizel, M. Pitiot, J.P. Siche, I. Bachelot, J.M. Mallion*
- 1620** Diabetic retinopathy in Oklahoma Indians with NIDDM: incidence and risk factors *E.T. Lee, V.S. Lee, R.M. Kingsley, M. Lu, D. Russell, N.R. Asal, C.P. Wilkinson, R.H. Bradford*

Short Report

- 1628** Use of premixed insulin among the elderly: reduction of errors in patient preparation of mixtures *C. Coscelli, G. Calabrese, D. Fedele, E. Pisu, C. Calderini, S. Bistoni, A. Lapolla, M.G. Mauri, A. Rossi, A. Zappella*

Behavioral Diabetes Series Articles

- 1631** Depression in adults with diabetes *P.J. Lustman, L.S. Griffith, J.A. Gavard, R.E. Clouse*

Editor in Chief

ALLAN L. DRASH, MD

Associate Editors

SILVA ARSLANIAN, MD
DOROTHY BECKER, MBBCH
JOSE F. CARO, MD
DONALD R. COUSTAN, MD
DAVID E. KELLEY, MD
RONALD E. LAPORTE, PHD
TREVOR ORCHARD, MD
LINDA SIMINERIO, RN
RENA R. WING, PHD

Editorial Assistant

MARY ORSCHIEDT

Review Editor

RALPH A. DEFONZO, MD

Associate Review Editors

K. GEORGE M.M. ALBERTI, MD
ELEUTERIO FERRANNINI, MD
RONALD KAHN, MD
ROBERT SHERWIN, MD
JAY SKYLER, MD

Editorial Assistant

SONDRA BAUER

Editorial Board

LINDA A. ANDERSON, PHD
ALAIN D. BARON, MD
MICHAEL BERELOWITZ, MD
DENNIS BIER, MD
ZACHARY BLOOMGARDEN, MD
DENIS DANEMAN, MD
JANICE A. DRASS, RN, BSN, CDE
JEFFREY S. FLIER, MD
ROBERT GELFAND, MD
FRANCISCO J. GOMEZ-PEREZ, MD
LINDA GONDER-FREDERICK, PHD
LEIF GROOP, MD
STEPHEN M. HAFFNER, MD
JEFFREY B. HALTER, MD
CLARISSA S. HOLMES, PHD
RODWIN A. JACKSON, MD
ALAN M. JACOBSON, MD
ORVILLE G. KOLTERMAN, MD
WEMARA LICHTY, PHD
MARIA LOPES-VIRELLA, MD, PHD
PIERO MICOSI, MD
WILLIAM J. RILEY, MD
ARLAN L. ROSENBLUM, MD
CHRISTOPHER P. SAUDEK, MD
ROBERT S. SCHWARTZ, MD
JAY M. SOSENKO, MD
NELSON B. WATTS, MD
RENA R. WING, PHD

Publisher

SUSAN H. LAU

Editorial Director

PETER BANKS

Managing Editor

SUSAN WHITE HALE

Assistant Managing Editor

GAIL SHAFFER

Production Editor

STACEY N. WAGES

Assistant Editors

KAREN L. INGLE
SARAH L. ROBERTS

Publications Assistant

PATRICIA M. WALSH

Advertising Manager

PEGGY B. ABBOTT

Advertising Assistant

PATTI THOMPSON

1640 Psychosocial problems and interventions in diabetes: a review of the literature R.R. Rubin, M. Peyrot

1658 Methodological issues in diabetes research: measuring adherence S.B. Johnson

Technical Review

1668 Pancreas transplantation for patients with diabetes mellitus American Diabetes Association

Position Statement

1673 Pancreas transplantation for patients with diabetes mellitus American Diabetes Association

1675 Supplement 4: Diabetes & Exercise '90

Commentaries

1814 CLIA 1988: impact on diabetes care R.E. Ratner

1818 Toward risk factor control for all patients with diabetes F. Whitehouse

1821 Thoughts on the dietary treatment of diabetes mellitus J.P. Bantle



point. counter point.



Glucolet[®] 2 *Automatic Lancing Device*

WITH UNIQUE FINGERSTIX[™] LANCET PROTECTION

Today even taking a fingerstick blood sample can be risky business. To counter the danger of an accidental needlestick injury, Glucolet[®] 2 features the unique protection of Fingerstix[™] Lancet.

Lancet is encased in a rigid, *disposable* endcap to eliminate the need for loading and recapping single lancets, and to keep the lancet needle recessed both

before and after you take your patient's blood sample.

Glucolet 2 offers you a simple, quick, and economical way to safely obtain blood samples.

For more information about Glucolet 2 and the other diabetes management products from Miles Inc, contact your Diagnostics Division Sales Representative.

Disposable Fingerstix[™] Lancet



and safer
Making diabetes easier to manage



Diagnostics Division

Miles Inc.
Elkhart, IN 46515

Zostrix®-HP... For Burning, Throbbing, Of Diabetic



Proven efficacy • • • • •

- 7 out of 10 patients treated with Zostrix®-HP (Capsaicin 0.075%) can expect significant pain relief'

Description: Zostrix/Zostrix-HP contain capsaicin in an emollient base containing benzyl alcohol, cetyl alcohol, glyceryl monostearate, isopropyl myristate, polyoxyethylene stearate blend, purified water, sorbitol solution and white petrolatum. Capsaicin is a naturally occurring substance derived from plants of the Solanaceae family with the chemical name trans-8-methyl-N-vanillyl-6-nonenamide. Capsaicin is a white crystalline powder with a molecular weight of 305.4. It is practically insoluble in water but very soluble in alcohol, ether and chloroform.

Action: Although the precise mechanism of action of capsaicin is not fully understood, current evidence suggests that capsaicin renders skin and joints insensitive to pain by depleting and preventing reaccumulation of substance P in peripheral sensory neurons. Substance P is thought to be the principal chemomediator of pain impulses from the periphery to the central nervous system. In addition, substance P has been shown to be released into joint tissues and activate inflammatory mediators involved with the pathogenesis of rheumatoid arthritis.

Indication: Zostrix/Zostrix-HP are indicated for the temporary relief of pain from rheumatoid arthritis, osteoarthritis and relief of neuralgias such as the pain following shingles (herpes zoster) or painful diabetic neuropathy.

Warnings: FOR EXTERNAL USE ONLY. Avoid contact with eyes and broken (open) or irritated skin. Do not bandage tightly. If condition worsens, or does not improve after 28 days, discontinue use of this product and consult your physician. **Keep this and all drugs out of the reach of children.** In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

Directions: Adults and children 2 years of age and older: Apply Zostrix/Zostrix-HP to affected area 3 to 4 times daily. Transient burning may occur upon application, but generally disappears in several days. Application schedules of less than 3 to 4 times a day may not provide optimum pain relief and the burning sensation may persist. **Wash hands if possible after applying Zostrix/Zostrix-HP avoiding areas where drug was applied.**

How Supplied:

Zostrix
0.7 oz (20 g) tube (NDC 52761-552-20)
1.5 oz tube (NDC 52761-552-45)
3.0 oz tube (NDC 52761-552-85)
Zostrix-HP
1.0 oz tube (NDC 52761-501-30)
2.0 oz tube (NDC 52761-501-60)
Store at room temperature 15°-30°C (59°-86°F)
U.S. Patent Nos. 4486450 and 4536404


GenDerm Corporation
Lincolnshire, IL 60069

Marketed by
GENDERM®



Relief Of The Lancinating Pain Neuropathy

**AKSAIN[®]
IS NOW
ZOSTRIX[®]-HP**



• • without systemic side effects^{1,2,3,4}


- No dizziness, drowsiness, headache or nausea
- No need for laboratory monitoring
- No drug interactions

REFERENCES

1. Donofrio P, Walker F, Hunt V, et al, The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double-blind, vehicle-controlled study. *Arch Intern Med.* 1991; 151:2225-2229.
2. Tandan R, Lewis CA, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy: effect on sensory function. *Diabetes Care.* 1992;15(1):15-18.
3. Tandan R, Lewis CA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy: controlled study with long-term follow-up. *Diabetes Care.* 1992;15(1):8-14.
4. Dailey GE, Muchmore DP, Springer JW, et al, The Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. *Diabetes Care.* 1992;15(2):159-165.

Zostrix[®]-HP
(Capsaicin 0.075%)
Topical Analgesic Cream

Presenting a diabetes education system that's as unique as the patients who use it.



“Touch Screen” technology lets patients tailor the program to fit their condition.

Every diabetes patient is different. And now there's an educational program that addresses those differences. It's called *About Your Diabetes*[™] — an interactive, touch screen system that can be customized for each patient's condition through a series of simple questions. So only relevant information is presented.

It Takes Less Time To Learn More

The personalized *About Your Diabetes* program is fun and easy to use for patients of all ages and literacy levels. With full-motion video, colorful graphics, plus on-

screen and audio prompts, patients are more likely to pay attention. As a result, they learn faster and remember more. An easy comprehension test helps ensure that everything is understood.

Quality Of Care And Efficiency Are Enhanced

When patients are actively involved in learning how to manage their disease, they realize

how important it is to comply with the treatment plan you provide. And that can help prevent acute problems. Also, because you can feel confident about the accurate, consistent information *About Your Diabetes* delivers, you can be more productive elsewhere in the office.

No Other System Compares

About Your Diabetes is a one-of-a-kind education system that offers all kinds of benefits to both you and your patients. To learn more about it, call 1-800-227-8772, ext. 884 today and ask for the Marketing Department.

USP DI VISUALIZED
**ABOUT YOUR
DIABETES**[™]
A Comprehensive Patient Education System

For hypertension

ONCE-DAILY[®]
ZESTRIL!
LISINAPRIL - STUART

Proven power over
24 hours*

PREGNANCY WARNING: ACE inhibitors should be discontinued as soon as pregnancy is detected (see Warnings).

Evaluation of the hypertensive patient should always include assessment of renal function (see Dosage and Administration). Angioedema has been reported with ACE inhibitors, including ZESTRIL (see Warnings).

*The antihypertensive effect may diminish at the end of the dosing interval.

Please see adjacent page for brief summary of prescribing information.

ZESTRIL[®] LISINAPRIL-STUART

Available in 5 mg (scored), 10 mg,
20 mg, 40 mg, tablets

BRIEF SUMMARY

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and death to the developing fetus. When pregnancy is detected, ZESTRIL should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

FOR FULL PRESCRIBING INFORMATION, SEE PACKAGE INSERT INDICATIONS AND USAGE

ZESTRIL is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.

In using ZESTRIL, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that ZESTRIL does not have a similar risk. (See WARNINGS.)

CONTRAINDICATIONS

ZESTRIL is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor.

WARNINGS

Angioedema: Angioedema of the face, extremities, lips, tongue, glottis, and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including ZESTRIL. In such cases, ZESTRIL should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, appropriate therapy, eg, subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway should be promptly provided. (See ADVERSE REACTIONS.)

Hypotension: Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of the use with ZESTRIL in salt/volume-depleted persons, such as those treated vigorously with diuretics or patients on dialysis. (See PRECAUTIONS, Drug Interactions, and ADVERSE REACTIONS.) In patients with severe congestive heart failure, with or without associated renal insufficiency, excessive hypotension has been observed and may be associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death. Because of the potential fall in blood pressure in these patients, therapy should be started under very close medical supervision. Such patients should be followed closely for the first two weeks of treatment and whenever the dose of ZESTRIL and/or diuretic is increased. Similar considerations apply to patients with ischemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If hypotension occurs, the patient should be placed in supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses which usually can be given without difficulty once the blood pressure has increased after volume expansion.

Neutropenia/Agranulocytosis: Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of ZESTRIL are insufficient to show that ZESTRIL does not cause agranulocytosis at similar rates. Marketing experience has revealed rare cases of neutropenia and bone marrow depression in which a causal relationship to lisinopril cannot be excluded. Periodic white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

Fetal/Neonatal Morbidity and Mortality: ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.

The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure.

These adverse effects do not appear to have resulted from intramammary ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of ZESTRIL as soon as possible.

Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the mother should be apprised of the potential hazards to her fetuses, and serial ultrasound examinations should be performed to assess the intra-amniotic environment.

If oligohydramnios is observed, ZESTRIL should be discontinued unless it is considered lifesaving for the mother. Contraction stress testing (CST), a nonstress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Infants with histories of in utero exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function. Lisinopril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.

No teratogenic effects of lisinopril were seen in studies of pregnant rats, mice, and rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in rats), and 0.8 times (in rabbits) the maximum recommended human dose.

PRECAUTIONS

General

Impaired Renal Function: As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including ZESTRIL, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death.

In hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine may occur. Experience with another angiotensin converting enzyme inhibitor suggests that these increases are usually reversible upon discontinuation of ZESTRIL and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy.

Some hypertensive patients with no apparent preexisting renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when ZESTRIL has been given concomitantly with a diuretic. This is more likely to occur in patients with preexisting renal impairment. Dosage reduction of ZESTRIL and/or discontinuation of the diuretic may be required.

Evaluation of the hypertensive patient should always include assessment of renal function. (See DOSAGE AND ADMINISTRATION.)

Hyperkalemia: In clinical trials hyperkalemia (serum potassium greater than 5.7 mEq/L) occurred in approximately 2.2% of hypertensive patients and 4.0% of patients with congestive heart failure. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in approximately 0.1% of hypertensive patients. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with ZESTRIL. (See Drug Interactions.)

Cough: Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is nonproductive, persistent, and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.

Surgery/Anesthesia: In patients undergoing major surgery or during anesthesia with agents that produce hypotension, ZESTRIL may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Information for Patients

Angioedema: Angioedema, including laryngeal edema, may occur especially following the first dose of ZESTRIL. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

Symptomatic Hypotension: Patients should be cautioned to report light-headedness especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with their physicians.

Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physicians.

Neutropenia: Patients should be told to report promptly any indication of infection (eg, sore throat, fever) which may be a sign of neutropenia.

Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intramammary ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

NOTE: As with many other drugs, certain advice to patients being treated with ZESTRIL is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions

Hypotension — Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ZESTRIL. The possibility of hypotensive effects with ZESTRIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ZESTRIL. If it is necessary to continue the diuretic, initiate therapy with ZESTRIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS, and DOSAGE AND ADMINISTRATION.) When a diuretic is added to the therapy of a patient receiving ZESTRIL, an additional antihypertensive effect is usually observed. Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic. (See DOSAGE AND ADMINISTRATION.)

Indomethacin: In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of ZESTRIL alone were compared to ZESTRIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced effect, although the difference between the two regimens was not significant.

Other Agents: ZESTRIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. No clinically important pharmacokinetic interactions occurred when ZESTRIL was used concomitantly with propranolol or hydrochlorothiazide. The presence of food in the stomach does not alter the bioavailability of ZESTRIL.

Agents Increasing Serum Potassium: ZESTRIL attenuates potassium loss caused by thiazide-type diuretics. Use of ZESTRIL with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.

Lithium: Lithium toxicity has been reported in patients receiving lithium with drugs which cause elimination of sodium, including ACE inhibitors. Lithium toxicity was usually reversed upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if ZESTRIL is administered concomitantly with lithium.

Contraception, Maternal, Impairment of Fertility

There was no evidence of a teratogenic effect when lisinopril was administered for 105 weeks to male and female rats at doses up to 90 mg/kg/day (about 56 times* the maximum recommended daily human dose) or when lisinopril was administered for 92 weeks to (male and female) mice at doses up to 135 mg/kg/day (about 84 times* the maximum recommended daily human dose).

*Based on patient weight of 50 kg.

Zestril[®] (Lisinopril)

Lisinopril was not mutagenic in the Ames microbial mutagen test with or without metabolic activation. It was also negative in a forward mutation assay using Chinese hamster lung cells. Lisinopril did not produce single strand DNA breaks in an in vitro alkaline elution rat hepatocyte assay. In addition, lisinopril did not produce increases in chromosomal aberrations in an in vitro test in Chinese hamster ovary cells or in an in vivo study in mouse bone marrow.

There were no adverse effects on reproductive performance in male and female rats treated with up to 300 mg/kg/day of lisinopril.

Pregnancy

Pregnancy Categories C (first trimester) and D (second and third trimesters). See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

Nursing Mothers: Milk of lactating rats contains radioactivity following administration of ¹⁴C lisinopril. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when ZESTRIL is given to a nursing mother.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

ZESTRIL has been found to be generally well tolerated in controlled clinical trials involving 2003 patients and subjects.

The most frequent clinical adverse experiences in controlled trials with ZESTRIL were dizziness (6.3%), headache (5.3%), fatigue (3.3%), diarrhea (3.2%), upper respiratory symptoms (3.0%), and cough (2.9%), all of which were more frequent than in placebo-treated patients. For the most part, adverse experiences were mild and transient in nature. Discontinuation of therapy was required in 6.0% of patients. In clinical trials, the overall frequency of adverse experiences could not be related to total daily dosage within the recommended therapeutic dosage range.

For adverse experiences which occurred in more than 1% of patients and subjects treated with ZESTRIL or ZESTRIL plus hydrochlorothiazide in controlled clinical trials, comparative incidence data are listed in the table below.

	Percent of Patients in Controlled Studies	
	ZESTRIL (n = 2003) ¹	ZESTRIL/Hydrochlorothiazide (n = 644)
	Incidence (discontinuation)	Incidence (discontinuation)
Dizziness	6.3 (0.6)	9.0 (0.9)
Headache	5.3 (0.2)	4.3 (0.5)
Fatigue	3.3 (0.2)	3.9 (0.5)
Diarrhea	3.2 (0.3)	2.6 (0.3)
Upper Respiratory Symptoms	3.0 (0.0)	4.5 (0.0)
Cough	2.9 (0.4)	4.5 (0.8)
Nausea	2.3 (0.3)	2.5 (0.2)
Hypotension	1.8 (0.8)	1.6 (0.5)
Rash	1.5 (0.4)	1.6 (0.2)
Orthostatic Effects	1.4 (0.0)	3.4 (0.2)
Asthenia	1.3 (0.4)	2.0 (0.2)
Chest Pain	1.3 (0.2)	1.2 (0.2)
Vomiting	1.3 (0.2)	1.4 (0.0)
Dyspnea	1.1 (0.0)	0.5 (0.2)
Dyspepsia	1.0 (0.0)	1.9 (0.0)
Paresthesia	0.8 (0.0)	2.0 (0.2)
Impotence	0.7 (0.2)	1.6 (0.3)
Muscle Cramps	0.6 (0.0)	2.8 (0.6)
Back Pain	0.5 (0.0)	1.1 (0.0)
Nasal Congestion	0.3 (0.0)	1.2 (0.0)
Decreased Libido	0.2 (0.1)	1.2 (0.0)
Vertigo	0.1 (0.0)	1.1 (0.2)

¹Includes 420 patients treated for congestive heart failure who were receiving concomitant digitalis and/or diuretic therapy.

Clinical adverse experiences occurring in 0.3% to 1.0% of patients in the controlled trials and, rarely, possibly drug related events reported in uncontrolled studies or marketing experience are listed below and, within each category, are in order of decreasing severity.

BODY AS A WHOLE: Chest discomfort, fever, flushing, malaise.

CARDIOVASCULAR: Myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see WARNINGS, Hypotension); angina pectoris, orthostatic hypotension, rhythm disturbances, tachycardia, peripheral edema, vasculitis, palpitation.

DIGESTIVE: Pancreatitis, hepatitis (hepatocellular or cholestatic jaundice), abdominal pain, anorexia, constipation, flatulence, dry mouth.

METABOLISM: Gout

MUSCULOSKELETAL: Joint pain, shoulder pain.

NERVOUS SYSTEM/PSYCHIATRIC: Depression, somnolence, insomnia, stroke, nervousness, confusion.

RESPIRATORY SYSTEM: Bronchitis, sinusitis, pharyngeal pain.

SKIN: Urticaria, pruritus, alopecia.

SPECIAL SENSES: Blurred vision.

UROGENITAL: Oliguria, progressive azotemia, acute renal failure, urinary tract infection.

A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, and fever.

ANGIOEDEMA: Angioedema has been reported in patients receiving ZESTRIL (0.1%). Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis, and/or larynx occurs, treatment with ZESTRIL should be discontinued and appropriate therapy instituted immediately. (See WARNINGS.)

HYPOTENSION: In hypertensive patients, hypotension occurred in 1.2% and syncope occurred in 0.1% of patients. Hypotension or syncope was a cause of discontinuation of therapy in 0.5% of hypertensive patients. (See WARNINGS.)

In patients with congestive heart failure, hypotension occurred in 5.0% and syncope occurred in 1.0% of patients. These adverse experiences were causes for discontinuation of therapy in 1.3% of these patients.

Fetal/Neonatal Morbidity and Mortality: See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

Cough: See PRECAUTIONS — Cough

Clinical Laboratory Test Findings

Serum Electrolytes: Hyperkalemia. (See PRECAUTIONS.)

Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 2.0% of patients with essential hypertension treated with ZESTRIL alone. Increases were more common in patients receiving concomitant diuretics and in patients with renal artery stenosis. (See PRECAUTIONS.) Reversible minor increases in blood urea nitrogen and serum creatinine were observed in approximately 9.1% of patients with congestive heart failure on concomitant diuretic therapy. Frequently, these abnormalities resolved when the dosage of the diuretic was decreased.

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.4 g% and 1.3 vol%, respectively) occurred frequently in patients treated with ZESTRIL but were rarely of clinical importance in patients without some other cause of anemia. In clinical trials, less than 0.1% of patients discontinued therapy due to anemia.

Other (Causal Relationship Unknown): Rarely, elevations of liver enzymes and/or serum bilirubin have occurred. In marketing experience, rare cases of neutropenia and bone marrow depression have been reported.

Overall, 2.0% of patients discontinued therapy due to laboratory adverse experiences, principally elevations in blood urea nitrogen (0.6%), serum creatinine (0.5%), and serum potassium (0.4%).

OVERDOSAGE

The oral LD₅₀ of lisinopril is greater than 20 g/kg in mice and rats. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Lisinopril can be removed by hemodialysis.

DOSAGE AND ADMINISTRATION

Initial Therapy: In patients with uncomplicated essential hypertension not on diuretic therapy, the recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 20-40 mg per day administered in a single daily dose. The antihypertensive effect may diminish toward the end of the dosing interval regardless of the administered dose, but most commonly with a dose of 10 mg daily. This can be evaluated by measuring blood pressure just prior to dosing to determine whether satisfactory control is being maintained for 24 hours. If it is not, an increase in blood pressure should be considered. Doses up to 80 mg have been used but do not appear to give greater effect. If blood pressure is not controlled with ZESTRIL alone, a low dose of a diuretic may be added. Hydrochlorothiazide, 12.5 mg has been shown to provide an additive effect. After the addition of a diuretic, it may be possible to reduce the dose of ZESTRIL.

Diuretic Treated Patients: In hypertensive patients who are currently being treated with a diuretic, symptomatic hypotension may occur occasionally following the initial dose of ZESTRIL. The diuretic should be discontinued, if possible, for two to three days before beginning therapy with ZESTRIL to reduce the likelihood of hypotension. (See WARNINGS.) The dosage of ZESTRIL should be adjusted according to blood pressure response. If the patient's blood pressure is not controlled with ZESTRIL alone, diuretic therapy may be resumed as described above.

If the diuretic cannot be discontinued, an initial dose of 5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, Drug Interactions.)

Concomitant administration of ZESTRIL with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium. (See PRECAUTIONS.)

Use in Elderly: In general, blood pressure response and adverse experiences were similar in younger and older patients given similar doses of ZESTRIL. Pharmacokinetic studies, however, indicate that maximum blood levels and area under the plasma concentration time curve (AUC) are doubled in older patients so that dosage adjustments should be made with particular caution.

Dosage Adjustment in Renal Impairment: The usual dose of ZESTRIL (10 mg) is recommended for patients with creatinine clearance > 30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance ≥ 10 mL/min < 30 mL/min (serum creatinine ≥ 3 mg/dL), the first dose is 5 mg once daily. For patients with creatinine clearance < 10 mL/min (usually on hemodialysis) the recommended initial dose is 2.5 mg. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.

Renal Status

Renal Status	Creatinine Clearance mL/min	Initial Dose mg/day
Normal Renal Function to Mild Impairment	> 30	10
Moderate to Severe Impairment	≥ 10 ≤ 30	5
Dialysis Patients	< 10	2.5 ¹

¹Dosage or dosing interval should be adjusted depending on the blood pressure response.

HOW SUPPLIED

5 mg Tablets (NDC 0030-0130) pink, capsule-shaped, biconvex, bisected, uncoated tablets, identified "ZESTRIL" on one side and "130" on the other side are supplied in bottles of 100 tablets and 1000 tablets, and unit dose packages of 100 tablets.

10 mg Tablets (NDC 0030-0131) pink, round, biconvex, uncoated tablets identified "ZESTRIL 10" debossed on one side, and "131" debossed on the other side are supplied in bottles of 100 tablets and 1000 tablets, and unit dose packages of 100 tablets.

20 mg Tablets (NDC 0030-0132) red, round, biconvex, uncoated tablets identified "ZESTRIL 20" debossed on one side, and "132" debossed on the other side are supplied in bottles of 100 tablets and 1000 tablets, and unit dose packages of 100 tablets.

40 mg Tablets (NDC 0030-0134) yellow, round, biconvex, uncoated tablets identified "ZESTRIL 40" debossed on one side, and "134" debossed on the other side are supplied in bottles of 100 tablets and unit dose packages of 100 tablets.

Store at room temperature. Protect from moisture, freezing, and excessive heat. Dispense in a tight container.


Rev B 02/92

STUART PHARMACEUTICALS
A business unit of ICI Americas Inc.
Wilmington, Delaware 19887 USA

GRP 1122

THE LATEST IN BLOOD GLUCOSE MONITORING

The simplicity is
ONE TOUCH.[®]
At a price that's a
light touch.



LifeScan set the standard for blood glucose monitoring with the revolutionary ONE TOUCH® Meters. Now we're introducing the new ONE TOUCH® BASIC™ Blood Glucose Meter. Priced around \$60, it's one terrific value. And it's the only low-price meter to incorporate proven, accurate ONE TOUCH® technology—the no wiping, no blotting, no timing technology that's used by over a million people. Easy-to-follow prompts guide users through three simple

I N T R O D U C I N G T H E N E W


ONE TOUCH® BASIC™

steps. They see accurate results in just 45 seconds. Available in drug stores and home healthcare centers across the country, the new ONE TOUCH BASIC Meter comes with a 30-day, money-back guarantee from LifeScan, a Johnson & Johnson company. We'll also support your recommendation 24 hours a day with a consumer technical services line and separate Healthcare Professional Hotline. For more information, please call 1 800 524-SCAN.



ONE TOUCH®
BASIC™

BLOOD GLUCOSE MONITORING SYSTEM



It's time you took a look at the basics.

No wiping, no blotting, no timing

Three simple steps to accurate test results

Accurate results in 45 seconds


Easy-to-read prompts in English and Spanish

Simple calibration

One-test memory stores last test result



*Press On/Off button,
insert test strip.
(The last test result appears.)*



*Apply sample.
No wiping. No blotting.
No timing.*



*Accurate results
in 45 seconds.*

Replaceable battery

Detects and notifies patient of most errors in
blood sample size and application

Signals when meter must be cleaned

Offers a wide test range, 0 - 600 mg/dL

Three-year warranty

Low price



ONE TOUCH[®]
BASIC[™]

BLOOD GLUCOSE MONITORING SYSTEM

©1992 LifeScan Inc.

For diabetes and life.

LIFESCAN^{INC.}


a Johnson & Johnson company

Milpitas, California 95035

*In NIDDM,
when diet alone fails,
Glucotrol
spells...*

Control



Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets 

*Please see brief summary
of GLUCOTROL[®] (glipizide)
prescribing information
on next page.*

When diet alone fails in non-insulin-dependent diabetes mellitus

The reasons to prescribe Glucotrol can pile up fast

Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets

Brief Summary of Prescribing Information

INDICATIONS AND USAGE: GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

CONTRAINDICATIONS: GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19, supp. 2:747-830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: Renal and Hepatic Disease: The metabolism and excretion of GLUCOTROL may be slowed in patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection, or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

Laboratory Tests: Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

Information for Patients: Patients should be informed of the potential risks and advantages of GLUCOTROL, of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

Carcinogenesis, Mutagenesis, Impairment of Fertility: A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Pregnancy: Pregnancy Category C: GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies

at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well-controlled studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

Nursing Mothers: Since some sulfonylurea drugs are known to be excreted in human milk, insulin therapy should be considered if nursing is to be continued.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas; GLUCOTROL should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL; if skin reactions persist, the drug should be discontinued. Porphyrria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

OVERDOSAGE: Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL, dialysis is unlikely to be of benefit.

DOSE AND ADMINISTRATION: There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL; in general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

Initial Dose: The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5-5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

Maximum Dose: The maximum recommended total daily dose is 40 mg.

Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.

HOW SUPPLIED: GLUCOTROL tablets are white, dye-free, scored, diamond-shaped, and imprinted as follows:

5 mg—Pfizer 411; 10 mg—Pfizer 412.

5 mg Bottles: 100's (NDC 0049-4110-66); 500's (NDC 0049-4110-73); Unit Dose 100's (NDC 0049-4110-41)

10 mg Bottles: 100's (NDC 0049-4120-66); 500's (NDC 0049-4120-73); Unit Dose 100's (NDC 0049-4120-41)


CAUTION: Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

Pfizer Roerig

Revised August 1990

40TH



*Annual
Advanced
Postgraduate
Course*

F A I R M O N T H O T E L

J A N U A R Y 2 2 - 2 4 , 1 9 9 3

S A N F R A N C I S C O , C A L I F O R N I A

**CHALLENGES AND CONTROVERSIES IN THE MANAGEMENT
OF DIABETES AND OTHER ENDOCRINE DISORDERS**

San Francisco is full of surprises. It's a place where dragons, bocce ball players, sidewalk stringed quartets, kite fliers and calligraphy street signs are a part of the everyday landscape...where you can scale home-grown alps in antique cable cars, walk across the Pacific (on the Golden Gate Bridge), serpentine down a street that looks like a slalom run and island-hop by ferry. It's a city of all seasons with mild winters, springlike summers, views that rival Rio's and stores on a par with Paris.

San Francisco has been called a "window of the world." The way the hills rise steeply out of a sparkling, island-studded bay is reminiscent of Hong Kong. At other times, when the harbor's a wind-whipped green, San Francisco assumes a Nordic look. The Marina, a forest of sail-boat spars, and Fisherman's Wharf, where the fishing fleet ties up, could be scenes painted in Portofino or St. Tropez. This is the far eastern edge of the Orient. The western edge of the continent. A port of gold.

Speakers

Sharon Anderson, MD
Associate Professor of Medicine
Oregon Health Sciences University
Portland, Oregon

John P. Bilezikian, MD
Professor of Medicine and of
Pharmacology; Chief, Division of
Endocrinology, Columbia University,
College of Physicians and Surgeons
New York, New York

Andrew J.M. Boulton, MD
Reader in Medicine/Consultant
Physician
Manchester Royal Infirmary
United Kingdom

Patrick J. Boyle, MD
Assistant Professor of Medicine
University of New Mexico
School of Medicine
Albuquerque, New Mexico

Glenn D. Braunstein, MD
Professor of Medicine, UCLA School of
Medicine; Chairman, Department of
Medicine, Cedars-Sinai Medical Center
Los Angeles, California

Brenda A. Broussard, RD, MPH
Nutrition Specialist
Indian Health Service Diabetes Program
Albuquerque, New Mexico

Michael Brownlee, MD
Professor of Medicine and Co-Director
of Diabetes Research Center,
Albert Einstein College of Medicine
Bronx, New York

John D. Brunzell, MD
Professor of Medicine
University of Washington
School of Medicine
Seattle, Washington

Philip E. Cryer, MD
Professor of Medicine and Director of
the Division of Endocrinology,
Diabetes, and Metabolism,
Washington University
School of Medicine
St. Louis, Missouri

Mayer B. Davidson, MD
Professor of Medicine, UCLA School of
Medicine; Director, Diabetes Program,
Cedars-Sinai Medical Center
Los Angeles, California

Larry Deeb, MD
Endocrinologist
Children's Clinic
Tallahassee, Florida

Stefan S. Fajans, MD
Professor Emeritus (Active) of Internal
Medicine
University of Michigan
School of Medicine
Ann Arbor, Michigan

Ruth Farkas-Hirsch, MS, RN, CDE
Diabetes Clinical Specialist,
University of Washington
School of Medicine
Seattle, Washington

John Foreyt, PhD
Director, Nutrition Research Center,
Baylor College of Medicine
Houston, Texas

John Galloway, MD
Clinical Research Fellow, Lilly Research
Laboratories; Professor of Medicine,
Indiana University School of Medicine
Indianapolis, Indiana

James R. Gavin, III, MD, PhD
Senior Scientific Officer
Howard Hughes Medical Institute
Bethesda, Maryland

David Goldstein, MD
Professor of Pediatrics, Medicine,
and Pathology
University of Missouri
School of Medicine
Columbia, Missouri

Douglas Greene, MD
Professor of Internal Medicine, Division
Chief, Endocrinology & Metabolism;
Director, Michigan Diabetes Research
and Training Center
Ann Arbor, Michigan

Scott Grundy, MD, PhD
Professor of Internal Medicine &
Biochemistry
University of Texas Southwestern
Medical Center at Dallas
Dallas, Texas

Debra Haire-Joshu, PhD, RN
Director, Diabetes Education Center,
DRTC, Research Associate
Professor of Medicine, Washington
University School of Medicine
St. Louis, Missouri

PREREGISTRATION FORM



Please register only one person per form. This form can be copied for additional registrants.

Section A: Personal Data

Academic degree(s) MD DO PhD RN RD RPH Other _____

Please print or type all information clearly

First Name _____ MI _____ Last Name _____

Title _____ Affiliation _____

Mailing Address _____

City _____ State _____ Country _____ Zip Code _____

Business Phone Number _____ Business Fax Number _____

Specialty Area (check one)

- Adult Endocrinology
- Epidemiology
- Family Practice
- Geriatrics
- Internal Medicine
- Nursing
- Nutrition
- Ophthalmology
- Ob/Gyn
- Pediatrics
- Pediatric Endocrinology
- Pharmacology
- Podiatry
- Psychology
- Public health
- Research
- Other (please indicate)

Type of Practice (check one)

- Clinic
- Corporate
- Hospital
- Private Practice
- Public Health
- HMO
- Research
- Academic
- Student
- Government/Military
- Other (please indicate)

Section B: Registration Fees

	Postmarked on or before December 4	Postmarked on or after December 5 or on site
ADA Professional Member (MD)	\$250	\$300
Nonmember (MD)	\$430	\$500
ADA Professional Member (non MD)	\$165	\$210
Nonmember (non MD)	\$250	\$310
Student/Fellow/Resident	\$125	\$170
One Day Registration	\$125	\$125

Indicate day that you will attend: _____

Guest Registration.....\$ 50.....\$ 50

One year membership to ADA is included in the non-member fees. You may decline membership with ADA; but you must still pay the non-member fee. Please authorize that you would like to become a member of ADA by signing: _____

Cancellation Policy

All cancellation requests must be submitted in writing and postmarked on or before December 28, 1992. Cancellations postmarked before November 6 will receive a full refund less \$50 processing fee. Cancellations postmarked between November 7 and December 28 will receive a registration refund less 50%. Cancellations postmarked after December 28, 1992 will not be honored.

Section C: Payment of Fees

Registration Fee \$ _____

Method of Payment (Checks and money orders must be made payable to the American Diabetes Association and must be payable in US funds drawn on a US bank.) Check Money Order American Express VISA MasterCard

Card Issued in the name of: (please print) _____ Card Number _____ Expiration Date: _____

I authorize American Diabetes Association to charge the total payment fee indicated on this form to my credit card.

Signature: _____

Section D: Mailing Information

Please complete and return this form, with payment to: American Diabetes Association, Department 0825, McLean, VA 22109-0825

If you have questions regarding registration, please contact the ADA Meetings Department at (703) 549-1500 ext. 330

Fax number (703) 836-7439

For ADA Use only: Check No: _____ B/PCharge: _____ AMEX/VISA/MC _____ Amount Received: _____ Date Received: _____

Deborah Hinnen, RN, MN, CDE
Program Director
Diabetes Treatment and Research Center
Wichita, Kansas

Irl Hirsch, MD
Director, Diabetes Care Center;
Associate Professor,
University of Washington
Seattle, Washington

Robert W. Jeffery, PhD
Professor of Epidemiology
University of Minnesota
School of Medicine
Minneapolis, Minnesota

Howard L. Judd, MD
Professor of Obstetrics and Gynecology,
UCLA; Executive Director, Division
of Reproductive Endocrinology,
UCLA and Cedars-Sinai
Los Angeles, California

John L. Kitzmiller, MD
Professor of Obstetrics
University of California-San Francisco
School of Medicine
San Francisco, California

Davida F. Kruger, MSN, RN, CDE
Clinical Nurse Specialist
Henry Ford Hospital
Detroit, Michigan

Harold E. Lebovitz, MD
Professor of Medicine
SUNY Health Science Center at Brooklyn
Brooklyn, New York

Donald E. McMillan, MD
Professor of Internal Medicine;
Professor of Physiology and
Biophysics; Co-Director State
Diabetes Center
University of South Florida
Diabetes Center
Tampa, Florida

Jerrold M. Olefsky, MD
Professor of Medicine
Veterans Affairs Medical Center
San Diego, California

Leopoldo Raij, MD
Chief, Nephrology/Hypertension,
Veterans Affairs Medical Center;
Professor of Medicine, University of
Minnesota School of Medicine
Minneapolis, Minnesota

Robert E. Ratner, MD
Associate Professor of Medicine,
George Washington University;
Director of Endocrinology,
Washington Hospital Center
Washington, D.C.

Gayle E. Reiber, PhD
Assistant Professor Health Services
and Epidemiology
Veterans Affairs Medical Center
Seattle, Washington

William Riley, MD
Professor of Pediatrics/Pathology and
Laboratory Medicine,
University of Florida
School of Medicine
Gainesville, Florida

David S. Schade, MD
Professor of Medicine
University of New Mexico
School of Medicine
Albuquerque, New Mexico

Aaron I. Vinik, MD
Professor of Internal Medicine &
Anatomy/Neural Biology, Institute at
Eastern Virginia Medical School;
Director of Diabetes Research
The Diabetes Institute
Norfolk, Virginia

Elizabeth Warren-Boulton, RN, MSN
President, Diabetes Education
Consulting Associates
Washington, D.C.

Thomas Wiegmann, MD
Professor of Medicine, University of
Kansas; Director, Renal Service,
Veterans Affairs Medical Center
Kansas City, Kansas

Duncan S. Wigg, PhD
Clinical Psychologist,
University of California-Irvine;
Department of Family Medicine-
Pepperdine University
Irvine, California

William Winter, MD
Associate Professor of Pathology and
Laboratory Medicine, Pediatrics, and
Immunology and Medical Microbiology
University of Florida
Gainesville, Florida

40th Advanced Postgraduate Course

The 40th Annual Advanced Postgraduate Course is presented in two concurrent tracks. Track I will feature sessions on diabetic neuropathy, new applications of standard therapy, unusual subsets of diabetes, controversies in clinical endocrinology, and upcoming therapies. Track II will provide an update on intensive insulin therapy, obesity as a risk factor, educational and counselling strategies for various ethnic populations, and the effects of standards of practice on the delivery of diabetes health care.

These advanced sessions have been specifically designed for endocrinologists, diabetologists, nurses, and other health care professionals who will benefit from an advanced program.

Program Objectives

1. To review the latest approaches in the management of type I and type II diabetes, and provide an overview of recent therapeutic developments.
2. To provide an update on current clinically-based research in the areas of malnutrition-related diabetes, Maturity-Onset Diabetes of Youth (MODY), and diabetes in the Black American.
3. To discuss issues of controversy on the topics of replacement estrogen therapy, the androgenized woman, and asymptomatic primary hyperparathyroidism.
4. To review the importance of obesity as a risk factor in patients with diabetes.
5. To compare and contrast effective treatment, educational, and counselling strategies for various ethnic populations.

HOTEL REGISTRATION FORM



Complete and return this form, with first night's deposit to:

Fairmont Hotel
Atop Nob Hill
San Francisco, CA 94108
(415) 772-5000 or (800) 527-4727

(Deadline for room reservations is December 28, 1992)

Date of Arrival _____ One King Bed _____
Time of Arrival _____ am/pm _____ Two Double Beds _____
Check in Time: 3:00pm _____ Two Twin Beds _____
Number of people _____
Sharing with _____

Date of Departure: _____

Suite requests must be authorized by American Diabetes Association's Meetings Department

Check Out Time: 1:00pm

Room Rate: \$135 flat rate—Main Building Interior
\$145 flat rate—Main Building Exterior
Roll-away beds cost \$30.

The Fairmont Hotel will make every effort to meet requests for specific room types and locations. However, on occasion, the hotel cannot accommodate such requests and reserves the right to provide alternate accommodations.

Guest Name: _____

Address: _____

City: _____ State: _____ Zip: _____

Phone (home): _____ (business) _____

All reservations must be accompanied by a first night's prepayment of \$135 or a MasterCard, Visa or American Express card number.

To qualify for available block space and rates, reservations must be received by December 28, 1992. Reservations received after this date will be confirmed on a space available basis at the next available rate category.

Please guarantee to my American Express, Visa or MasterCard number _____ Exp. _____

Prepayment check enclosed. Amount \$ _____

Prepayment Requirement

Please enclose a U.S. check drawn on a U.S. bank or American Express, MasterCard or Visa card number and expiration date to be guaranteed as prepayment, payable to the Fairmont Hotel. To receive a full refund, cancellation must be received by the hotel no later than 72 hours prior to the arrival date (not including the arrival date).

P R O G R A M

Track I

FRIDAY, JANUARY 22, 1993

SESSION 1: *Diabetic Neuropathy*

8:30 a.m. - 9:15 a.m. Pathophysiology and Results in New Clinical Studies with Aldose Reductase Inhibitors
Douglas Greene, MD

9:15 a.m. - 10:00 a.m. Unusual Clinical Aspects of Diabetic Neuropathy
Andrew J. M. Boulton, MD

10:00 a.m. - 11:00 a.m. Break

11:00 a.m. - 11:45 a.m. New Treatment Modalities for Diabetic Neuropathy
Aaron I. Vinik, MD

11:45 a.m. - 12:30 p.m. Hypoglycemia-Associated Autonomic Failure in the Absence of Autonomic Neuropathy
Philip E. Cryer, MD

SESSION 2: *New Applications of Standard Therapy*

2:00 p.m. - 2:45 p.m. Microalbuminuria: Harbinger of Clinical Nephropathy?
Thomas Wiegmann, MD

2:45 p.m. - 3:30 p.m. Role of Antihypertensive Treatment in Early Diabetic Nephropathy
Leopoldo Raij, MD

3:30 p.m. - 4:15 p.m. Break

4:15 p.m. - 5:00 p.m. Do Low Protein Diets Delay Renal Insufficiency in Patients with Early Diabetic Nephropathy?
Sharon Anderson, MD

5:00 p.m. - 5:45 p.m. Alternative Drug Treatment of Hypertriglyceridemia in Diabetes
Scott Grundy, MD, PhD

SATURDAY, JANUARY 23, 1993

SESSION 3: *Unusual Subsets of Diabetes Mellitus*

8:30 a.m. - 9:15 a.m. Type II Diabetes in Black Americans
Harold E. Lebovitz, MD

9:15 a.m. - 10:00 a.m. Atypical Diabetes in Younger Black Americans
William Winter, MD

10:00 a.m. - 11:00 a.m. Break

Track I

11:00 a.m. - 11:45 a.m. Diabetes When Food is Scarce (Malnutrition-Related Diabetes)
Donald E. McMillan, MD

11:45 a.m. - 12:30 p.m. Inheritance and Pathogenesis of "Maturity-Onset Diabetes of Youth" (MODY)
Stefan S. Fajans, MD

SESSION 4: *Controversies in Clinical Endocrinology*

2:00 p.m. - 2:45 p.m. Replacement Estrogen Therapy - Yes Or No? If So, How?
Howard L. Judd, MD

2:45 p.m. - 3:30 p.m. The Androgenized Woman - From Simple Hirsutism to Virilization
Glenn D. Braunstein, MD

3:30 p.m. - 3:45 p.m. Break

3:45 p.m. - 4:30 p.m. New Approaches to the Evaluation and Treatment of Patients with Asymptomatic Primary Hyperparathyroidism
John P. Bilezikian, MD

SUNDAY, JANUARY 24, 1993

SESSION 5: *Therapies Just Around the Corner*

8:00 a.m. - 8:40 a.m. Future Therapies of IDDM: Are We There Yet?
Robert Ratner, MD

8:40 a.m. - 9:20 a.m. Maintenance of Endogenous Insulin Secretion in New Onset Type I Diabetes
William Riley, MD

9:20 a.m. - 10:00 a.m. New Insulins and Insulinotropic Agents
John Galloway, MD

10:00 a.m. - 11:00 a.m. Break

11:00 a.m. - 11:30 a.m. Aminoguanidine - An Inhibitor of Advanced Glycosylation End Products (AGE)
Michael Brownlee, MD

11:30 a.m. - 12:00 noon Metformin, Phenformin's (DBI) Cousin
Mayer B. Davidson, MD

12:00 noon - 12:30 p.m. Thiazolidinediones - Restorer of Insulin Sensitivity
Jerrold M. Olefsky, MD

S C H E D U L E

Track II

FRIDAY, JANUARY 22, 1993

SESSION 1: *Intensive Insulin Therapy Update*

CHAIR: *Ruth Farkas-Hirsch, MS, RN, CDE*

8:00 a.m. - 8:40 a.m. Complications of Intensive Therapy
Patrick J. Boyle, MD

8:40 a.m. - 9:20 a.m. Controversies of Insulin Management
During Surgery
Irl Hirsch, MD

9:20 a.m. - 10:00 a.m. Critical Role of the Nurse Specialist in
Intensive Management
David Kruger, MSN, RN, CDE

10:00 a.m. - 11:00 a.m. Break

11:00 a.m. - 11:45 a.m. Assessment of Glycemic Control
David Goldstein, MD

11:45 a.m. - 12:30 p.m. Trends in the Management of Brittle
Diabetes
David S. Schade, MD

SESSION 2: *Obesity As a Risk Factor: More Than Meets the Eye*

CHAIR: *Debra Haire-Joshu, PhD, RN*

2:00 p.m. - 2:45 p.m. Dilemma of Weight Gain After
Smoking Cessation
Debra Haire-Joshu, PhD, RN

2:45 p.m. - 3:30 p.m. Treating Obesity: Is It Worth the Effort?
John D. Brunzell, MD

3:30 p.m. - 4:15 p.m. Break

4:15 p.m. - 5:00 p.m. Can Successful Long Term Weight
Loss Be Predicted?
John Foreyt, PhD

5:00 p.m. - 5:45 p.m. Is Diet-Induced Weight Cycling a
Health Risk?
Robert Jeffery, PhD

Track II

SATURDAY, JANUARY 23, 1993

SESSION 3: *Individualized Educational and Counselling Strategies for Various Ethnic Populations*

CHAIR: *Deborah Hinnen, RN, MN, CDE*

8:30 a.m. - 9:15 a.m. Does Counselling Really Improve
Compliance?
Duncan Wigg, PhD

9:15 a.m. - 10:00 a.m. Educating the Low Literacy Client
Deborah Hinnen, RN, MN, CDE

10:00 a.m. - 11:00 a.m. Break

11:00 a.m. - 11:45 a.m. Cultural and Ethnic Issues
Impacting Health
James R. Gavin, III, MD, PhD

11:45 a.m. - 12:30 p.m. Barriers to Effective Nutrition
Education: Clinical and Community Approaches
Brenda Broussard, RD, MPH

SUNDAY, JANUARY 24, 1993

SESSION 4: *The Effects of Standards of Practice on the Delivery of Diabetes Health Care*

CHAIR: *Elizabeth Warren-Boulton, RN, MSN, CDE*

8:30 a.m. - 9:15 a.m. Standards for Medical Care
Larry Deeb, MD

9:15 a.m. - 10:00 a.m. Guidelines for Foot Care
Gayle E. Reiber, PhD

11:00 a.m. - 11:45 a.m. Guidelines for the Care of the
Pregnant Diabetic Woman
John L. Kitzmiller, MD

10:00 a.m. - 11:00 a.m. Break

11:45 a.m. - 12:30 a.m. Standards for Patient Education
Elizabeth Warren-Boulton, RN, MSN, CDE

GENERAL INFORMATION

Exhibits

An exposition with over 30 companies will feature the most up-to-date products and services available for diabetes treatment. Time is included in the course program for attendees to visit the exhibits to review the latest developments in diabetes care. Morning coffee breaks will be served in the exhibit hall. **NO ONE UNDER THE AGE 16 WILL BE PERMITTED IN THE EXHIBIT HALL.**

Exhibit Hours: Friday, January 22 10:00am - 2:00pm
 Saturday, January 23 10:00am - 2:00pm

Registration

Return the enclosed registration form with payment by check, money order, MasterCard, VISA or American Express to the American Diabetes Association. All checks and money orders must be payable in US funds and drawn on a US bank. Registration is not official until payment is received.

The registration fee (see schedule below) includes course materials and admission to all sessions, exhibits and social events. Registration will be confirmed if postmarked by December 28, 1992. Students, fellows and residents must include certification of status to obtain the reduced rate. Guest registration will admit individuals to the exhibit floor and social functions only.

Registration Fees

	Postmarked on or before December 4	Postmarked on or after December 5 or on-site
ADA Professional Member [MD]	\$250	\$300
Nonmember [MD]	\$430	\$500
ADA Professional Member [nonMD]	\$165	\$210
Nonmember [nonMD]	\$250	\$310
Student/Fellow/Resident	\$125	\$170
One Day Registration	\$125	\$125 Day
Guest Registration	\$ 50	\$ 50

One year membership to American Diabetes Association is included in the non-member fees. You may decline membership with American Diabetes Association; but you must still pay the non-member fee. A complete membership application will be mailed to you upon receipt of registration.

Cancellation Policy

All cancellation requests must be submitted in writing and postmarked on or before December 28, 1992. Cancellations postmarked before November 6 will receive a full refund less

\$50 processing fee. Cancellations postmarked between November 7 and December 28 will receive a registration refund less 50%. Cancellations postmarked after December 28, 1992 will not be honored.

Registration/Information Desk Hours

Thursday, January 21 4:00pm - 9:00pm
Friday, January 22 7:30am - 6:00pm
Saturday, January 23 7:30am - 5:00pm
Sunday, January 24 7:30am - 2:00pm

AADE Advanced Studies Institute for Diabetes Education (ASIDE)

Courses from the American Association of Diabetes Educators' Advanced Studies Institute for Diabetes Education will again be offered in conjunction with the ADA Postgraduate Course. The Institute consists of a series of interrelated courses emphasizing experiential learning activities. Certain education and experience requirements must be met in order to be admitted to the Institute. Once admitted, candidates must successfully complete six core courses and six electives in areas which include diabetes education, complications, health care systems and settings, psychosocial, research, and business management.

The core course on Diabetes Complications and elective courses on "Teaching Patients with Low Literacy Skills" will be scheduled on free afternoons so as not to conflict with the Postgraduate sessions. Significant preparatory work must be completed prior to the onsite workshops and enrollment is limited to 32 students per course.

Further information about registration materials and deadlines for ASIDE are available ONLY from the AADE National Office, 444 North Michigan Avenue, Suite 1240, Chicago, Illinois 60611; telephone 1-800-338-DMED. The ASIDE fee is separate from the Postgraduate Course registration fee.

Accreditation


The American Diabetes Association is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The American Diabetes Association is approved as a provider of continuing education in nursing by the Virginia Nurses' Association, which is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

ADA also has applied to the American Dietetic Association and the American Association of Family Physicians for accreditation.

Credits will be distributed at the ADA Registration/Information Desk between 12:30pm and 2:00pm on Sunday, January 24.

DEADLINE FOR RECEIPT OF ABSTRACTS IS JANUARY 8, 1993



53rd SCIENTIFIC SESSIONS
12 - 15 June 1993 Las Vegas, Nevada

INSTRUCTIONS FOR PREPARATION OF ABSTRACTS

1. **Originality of work, adequacy of data, and clarity of exposition are the determinants in the selection of abstracts.** Make abstracts as informative as possible, including a brief statement of the purpose of the study or why it was done, the methods or what was done, the results observed, and the author's conclusions based on the results. Actual data should be summarized. It is inadequate to state "The results will be discussed" or "The data will be presented." Tables may be used to present data.

2. **Abstracts are not eligible for consideration if the paper has been presented at another national or international meeting, or will be published before ADA's Scientific Sessions.**

3. **The original abstract should be clear and within the border of the form, and is limited to the space provided.** If typed, use carbon ribbon or slightly used black silk ribbon. (New ribbons smudge; old one reproduce too faintly.) Practice typing the abstract in a rectangle 4 3/16" X 6 3/16" before using this form. An abstract printed by a laser printer or good-quality dot matrix printer is acceptable. However, the printed abstract must be an original copy and must be submitted on the abstract form. As with typed abstracts, the text must be within the border of the form. Those exceeding the border will not be accepted.

4. **The signature of an active member of the Professional Section of the American Diabetes Association is required to validate the abstract.** Members who sponsor non-members should verify that the latter are conforming to the rules.

5. **An individual (member or non-member) may only appear on two abstracts, and may appear as first author on only one abstract.** A member can appear as author, co-author, or sponsor. A non-member can appear as author or co-author.

6. **The final decision with respect to selection, programming, and/or publication of any abstract will be made by the Scientific Sessions Meeting Committee.**

7. **The original and three copies of the abstract must be provided.**

8. **Abstract headings must follow a specified format.** The format is:

a. Only the first letters of major words in the title should be capitalized. Do not use subtitles (e.g., Methods, Results) within the body of the abstract.

b. Author(s) complete first and last names should be listed and capitalized.

c. Author(s) who are members of ADA's Professional Section must be indicated by an asterisk.

d. Do not list degrees (e.g., MD, RN, RD) academic title(s), and institutional affiliation(s).

e. Include city and state or country of origin of work; do not include street address and zip code.

f. Headings should begin to the immediate right of the box located in the upper left corner of the abstract area.

Example:

The Mechanism of Glucosamine-Induced Insulin Release, FRANZ M. MATSCHINSKY*, JANINA KOTLER-BRAJTBURG, JEANETTE ELLERMAN, and MARSHA ROGERS, St. Louis, MO

9. **The first line of the text of the abstract and the first line of any subsequent paragraphs should be indented three spaces.**

10. **The use of standard abbreviations is desirable.** Examples include kg, g, mg, ml, L (liter), meq, m (meter), mM (millimoles per liter), / (per), and % (percent). Place special or unusual abbreviations in parentheses after the full word the first time they appear. Use numerals to indicate numbers, except to begin sentences.

11. **Nonproprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters; the first initial of a proper name is capitalized, e.g., aspirin (Bufferin).**

12. **Simple tables or special symbols may be included if they fit within the rectangular form provided.** Material that cannot be typed should be drawn in India ink.

13. **Do not fold the Abstract Form or copies.** They should be mailed with cardboard backing FIRST CLASS, or AIR MAIL when applicable, and addressed as follows:

Scientific Sessions Meeting Committee
American Diabetes Association
P.O. Box 26427
Alexandria, VA 22313-6427

14. **Changes to abstracts may not be made after submission.** Accepted abstracts will be printed as submitted. They should be carefully written and edited before submission.

15. **Abstracts must be received at the National Center by January 8, 1993.** Abstracts received after the deadline, regardless of the postmark date, will not be accepted.

16. **Provide one typed 3" X 5" white index card for each author named on the abstract to be listed in the index of the program.**

The author's name and degree(s) should be typed in the top left corner of the card. The abstract category should be typed in the center of the card.

Example:

SMITH, Leslie E.*, MD, PhD
Category -- Lipids and Lipoproteins

17. If you wish acknowledgement that an abstract was received by ADA, the Abstract Form should be accompanied by a postage-paid postal card addressed to the corresponding author; the reverse side of the card should indicate the title of the abstract and the name(s) of all author(s).

18. A non-refundable processing fee of US\$25.00 must accompany each Abstract Form submitted to the American Diabetes

Association. Payment must be in the form of a check or money order made payable to the American Diabetes Association, or by a major credit card. Purchase orders are unacceptable. Foreign payments must be prepaid in U.S. funds and drawn on a U.S. bank.

19. Additional Abstract Forms may be obtained from Jill Thompson, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314.

20. Papers are to be presented by the first author listed.

21. Oral presentations at the Scientific Sessions will be limited to 10 minutes to allow time for discussion.

22. Presenters must pay the registration fee for attendance at the Annual Meeting.

CHECKLIST FOR PREPARATION OF ABSTRACTS

Before mailing, please check your abstract for the following:

- Are only the first letters of major words in the title capitalized?
- Are all letters in the author(s), co-author(s), and sponsor(s) names capitalized in the title and do the author(s)' complete first names precede last names?
- Are asterisks only used to designate active members of the Professional Section of the American Diabetes Association on the Abstract Form?
- Are degrees, academic titles, institutional affiliations, street address, and zip code not listed in heading of abstract?
- Does the heading of the abstract, including title, author(s) name(s), city, and state, begin to the right of the box located in the left corner of the abstract typing area of the Abstract Form?
- Is the first line of the text of abstract and first line of subsequent paragraphs indented three spaces?
- Has the Abstract Form been signed by an active member of the Professional Section of the American Diabetes Association?
- Has the appropriate category number been filled in on the Abstract Form?
- Are three (3) photocopies enclosed with the Abstract Form?
- Has a typed index card with name, degree(s), and abstract category been provided for EACH author? If an acknowledgement is desired, is a postage-paid postal card addressed to the corresponding author enclosed?
- Is a US\$25.00 processing fee, in check or money order form and made payable to the American Diabetes Association, enclosed for each abstract submitted? Or, has credit card information, including signature, been provided?

1993 ABSTRACT CATEGORIES

Select one two-digit category number and enter it on the appropriate line on the abstract form:

- 01 Clinical Diabetes
- 02 Complications, Macrovascular
- 03 Complications, Microvascular
- 04 Complications, Neuropathy
- 05 Complications, Other
- 06 Epidemiology
- 07 Exercise
- 08 Forms of Therapy
- 09 Genetics
- 10 Health Care Delivery
- 11 Health Education
- 12 Hormone Action
- 13 Hormone, Others
- 14 Hormone Receptors
- 15 Immunology/Immunopathology
- 16 Insulin Action
- 17 Insulin Synthesis/Secretion
- 18 Lipids/Lipoproteins/Atherosclerosis
- 19 Metabolism, In Vitro
- 20 Metabolism, In Vivo
- 21 Microvascular
- 22 New Technologies
- 23 Nutrition/Obesity
- 24 Pregnancy
- 25 Psychosocial/Behavioral Medicine
- 26 Signal Transduction
- 27 Transplantation

TYPE ABSTRACT WITHIN BOX



ABSTRACT FORM

This form must be signed by an active member of the Professional Section of the American Diabetes Association.

IMPORTANT

The instructions on pages 1 and 2 must be followed exactly for abstracts to be considered.

List names, degrees, address, and telephone and fax numbers of author who should receive correspondence (please type or print):

Name _____

Address _____

City _____ State _____ Zip _____

Country _____

Work Number: () _____

Fax Number: () _____

The sponsoring member agrees that the material submitted herein conforms with the instructions listed on pages 1 and 2.

MEMBER'S SIGNATURE

PRINTED NAME

CHECK ONE:

_____ Poster Session Only

_____ Oral Presentation Only

_____ No Preference

The author's wishes will be followed if possible.

ABSTRACT CATEGORY NUMBER: _____

(See two-digit category numbers listed on page 2)

Large empty box for typing the abstract content.

Please retype title: _____

Key Words for Program Index: Please list 1 or 2 words that relate to the content of your abstract for indexing purposes. You may use words in the category listing or choose other more specific terms. The word diabetes is unacceptable. (Please print clearly.)

1. _____ 2. _____

Method of Payment

I have enclosed a check/money order in the amount of US\$25.00 for each abstract submitted.

I authorize the American Diabetes Association to charge \$ _____ to my credit card for my abstract processing fee.

[] American Express [] VISA [] Mastercard

Card issued in name of (please print): _____

Card Number: _____ Expiration Date: _____

Signature: _____

FOR OFFICE USE ONLY

Payment Received?

_____ Yes _____ No

Abstract No. _____


Reviewer Group _____

Status _____

PN _____

DO *NOT* WRITE ON THIS PAGE

***N**OW, MANAGEMENT OF
TYPE II DIABETES HAS
TAKEN ON A NEW SHAPE*



GLYNASE™ PRESTAB™
Tablets (glyburide) **3mg**



UNIQUE DESIGN,




GLYNASE PresTab: Designed for greater flexibility

A patented manufacturing process has created a unique tablet* that divides easily and evenly in half at the press of a finger. This breakthrough in dosing flexibility enables ease of titration for the individual dosing needs of your patients.

*Upjohn Utility Patent #4735805.



IMPROVED ABSORPTION



GLYNASE PreTab: Designed for control at a lower dose

GLYNASE PreTab 3 mg is a new formulation of glyburide, providing improved, more consistent bioavailability due to enhanced absorption.[†] Now it is possible to provide effective blood glucose control with a lower dose.



GLYNASE PreTab: Designed to deliver

GLYNASE PreTab was designed to help you meet your management goals. Now, as an adjunct to diet and exercise, your patients can get the trusted benefits of glyburide efficacy and safety^{†1}—with ease of titration and improved absorption. Patients should be retitrated when transferred from Micronase[®] Tablets (glyburide) or other oral hypoglycemic agents.

[†]All sulfonylureas are associated with a risk of hypoglycemia. Proper patient selection, dosage, and instructions are important.

Please see the following page for brief summary of prescribing information.

GLYNASE[™] PRESTAB[™]
Tablets (glyburide) **3mg**



Designed with management in mind


GLYNASE™ PRESTAB™

Tablets (glyburide) 3mg



Ease of titration towards maximum efficacy

- The 3-mg tablet breaks easily and evenly to titrate in 1.5-mg increments, providing eight different doses ranging from 1.5 mg to 12 mg.
- The 1.5-mg tablet may be easily broken to provide the infrequent .75-mg dose.
- Patients should be retitrated when transferred from Micronase® (glyburide) or other oral hypoglycemic agents.



Start with one-half or one 3-mg GLYNASE Prestab daily.

	GLYNASE Prestab	Micronase	Glucotrol*	Diabinese†
Usual Starting Dose	1.5 mg to 3 mg	2.5 mg to 5 mg	5 mg	250 mg
Daily Dosage Range	.75 mg to 12 mg	1.25 mg to 20 mg	2.5 mg to 40 mg	100 mg to 750 mg



*Glucotrol (glipizide) is a trademark of Roerig.
†Diabinese (chlorpropamide) is a trademark of Pfizer Laboratories.

GLYNASE™ Prestab™ Tablets (glyburide)

INDICATIONS AND USAGE

GLYNASE Prestab Tablets are indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. During maintenance programs, GLYNASE Prestab should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Controlling blood glucose in non-insulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes.

CONTRAINDICATIONS

1. Known hypersensitivity or allergy to the drug.
2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.
3. Type I diabetes mellitus, as sole therapy.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY

The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 1970;19(suppl 2):747-830).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 g per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLYNASE Prestab and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS

Bioavailability studies have demonstrated that GLYNASE Prestab Tablets 3mg provide serum glyburide concentrations that are not bioequivalent to those from MICRONASE Tablets 5 mg. Therefore, the dose should be retitrated when a patient is transferred from MICRONASE or Diabeta or other oral hypoglycemic agents.

General

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection and dosage and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may increase the risk of serious hypoglycemic reactions. Elderly, debilitated, or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking β-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used. **Loss of Control of Blood Glucose:** In stabilized diabetic patients exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to discontinue GLYNASE Prestab and administer insulin. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as secondary failure. **Information for Patients:** Patients should be informed of the potential risks and advantages of GLYNASE Prestab and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Laboratory Tests

Response to GLYNASE Prestab Tablets should be monitored by frequent urine glucose tests and periodic blood glucose tests. Measurement of glycosylated hemoglobin levels may be helpful in some patients.

Drug Interactions

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and β-adrenergic blocking agents. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. It is not known whether this reaction also occurs with intravenous, topical, or vaginal miconazole.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies in rats at doses up to 300 mg/kg/day for 18 months showed no carcinogenic effects. Glyburide is

nonmutagenic when studied in the Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay. No drug-related effects were noted in a 2-year oncogenicity study of glyburide in mice.

Pregnancy

Teratogenic Effects: Pregnancy Category B

Reproduction studies in rats and rabbits have revealed no evidence of impaired fertility or harm to the fetus due to glyburide. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Many experts recommend that insulin be used during pregnancy to maintain blood glucose as close to normal as possible. **Nonteratogenic Effects:** Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently for agents with prolonged half-lives. If used during pregnancy, GLYNASE Prestab should be discontinued at least 2 weeks before the expected delivery date.

Nursing Mothers

Some sulfonylurea drugs are known to be excreted in human milk. Therefore, a decision should be made whether to discontinue nursing or discontinue drug. Insulin therapy should be considered if diet alone is not adequate for controlling blood glucose.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Hypoglycemia: See Precautions and Overdosage sections. **Gastrointestinal Reactions:** Cholestatic jaundice and hepatitis may occur rarely; GLYNASE Prestab Tablets should be discontinued if this occurs. Liver function abnormalities have been reported. Gastrointestinal disturbances (eg, nausea, epigastric fullness, and heartburn) are the most common reactions and occurred in 1.8% of patients during clinical trials. They tend to be dose related and may disappear when the dose is reduced. **Dermatologic Reactions:** Allergic skin reactions (eg, pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions) occurred in 1.5% of patients during trials. These may be transient and may disappear despite continued use of glyburide; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic Reactions: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas. **Metabolic Reactions:** Hepatic porphyria and disulfiramlike reactions have been reported with sulfonylureas; however, hepatic porphyria has not been reported with glyburide, and disulfiramlike reactions have been reported very rarely. Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone (ADH). The syndrome of inappropriate ADH (SIADH) secretion has been reported with certain other sulfonylureas, and it has been suggested that these sulfonylureas may augment the peripheral (antidiuretic) action of ADH or increase release of ADH, or both. **Other Reactions:** Changes in accommodation or blurred vision, or both, have been reported with glyburide and other sulfonylureas. In addition to dermatologic reactions, allergic reactions such as angioedema, arthralgia, myalgia, and vasculitis have been reported.

OVERDOSAGE

Overdosage of sulfonylureas, including glyburide, can produce hypoglycemia. Mild hypoglycemic symptoms should be treated aggressively with oral glucose and adjustments in drug dosage or meal patterns, or both. Close monitoring should continue until the physician is assured that patient is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurologic impairment occur infrequently but constitute medical emergencies requiring immediate hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, because hypoglycemia may recur after apparent clinical recovery.

HOW SUPPLIED

GLYNASE Prestab Tablets are available as 1.5-mg and 3-mg tablets.

Caution: Federal law prohibits dispensing without a prescription.

Store at controlled room temperature 15°-30°C (59°-86°F). Dispense in well closed containers with safety closures. Keep container tightly closed.

Diabeta is a trademark of Hoechst-Roussel Pharmaceuticals, Inc.

The Upjohn Company
Kalamazoo, MI 49001 USA

B-1-S

Reference

1. Data on file, The Upjohn Company, Kalamazoo, Mich.

Upjohn The Upjohn Company
Kalamazoo, MI 49001

June 1992

USJ4067.00

Diabetic Medicine

Journal of the British Diabetic Association

EDITORIAL

- Diabetes and the Clinical Standards Advisory Group** *D. R. R. Williams* 695

REVIEW

- Blood Glucose Control and Diabetic Microvascular Complications: Long-term Effects of Near-normoglycaemia** *K. F. Hanssen, H.-J. Bangstad, O. Brinchmann-Hansen, K. Dahl-Jørgensen* 697

ORIGINAL ARTICLES

- Parity, Ethnic Group and the Prevalence of Type 2 Diabetes: The Coventry Diabetes Study** *D. Simmons* 706
- The Prevalence, Detection, and Epidemiological Correlates of Peripheral Vascular Disease: A Comparison of Diabetic and Non-diabetic Subjects in an English Community** *D. P. Walters, W. Gatling, M. A. Mullee, R. D. Hill* 710
- Clinical Examination Versus Neurophysiological Examination in the Diagnosis of Diabetic Polyneuropathy** *G. D. Valk, J. J. P. Nauta, R. L. M. Strijers, F. W. Bertelsmann* 716
- The Effect of Weight-bearing Pressure on the Plantar Circulation in Diabetes Mellitus** *E. Proano, H. Määttäinen, L. Perbeck, G. Solders, I. Turan* 722
- Prevalence of Haemochromatosis Amongst Patients with Diabetes Mellitus** *B. M. Singh, R. A. Grunewald, M. Press, B. R. Muller, P. H. Wise* 730
- Effect of Chronic ACE Inhibition on Glucose Tolerance and Insulin Sensitivity in Hypertensive Type 2 Diabetic Patients** *G. Seghieri, W. Yin, C. Boni, G. Sanna, R. Anichini, G. Bartolomei, E. Ferrannini* 732
- Influence of Ripeness of Banana on the Blood Glucose and Insulin Response in Type 2 Diabetic Subjects** *K. Hermansen, O. Rasmussen, S. Gregersen, S. Larsen* 739
- Distinguishing Between Persistent and Transient Impaired Glucose Tolerance Using a Prediction Model** *D. M. Bourn, S. M. Williams, J. I. Mann* 744

CLINICAL PRACTICE

- Foot Infections in Diabetes are Rarely Due to a Single Microorganism** *J. A. Hunt* 749
- An Audit of the Management and Outcome of Hospital Inpatients With Diabetes: Resource Planning Implications for the Diabetes Care Team** *E. A. Masson, I. A. MacFarlane, E. Power, M. Wallymahmed* 753
- The Effect of a City-wide Mass Media Campaign on the Public Awareness of Diabetes** *N. D. Penn, C. Stevenson, C. McMahon, H. J. Bodansky* 756

BDA REPORT

- A Proposal for Continuing Audit of Diabetes Services** *D. R. R. Williams, P. D. Home and Members of a Working Group of the Research Unit of the Royal College Physicians and British Diabetic Association* 759

CASE REPORT

- Evidence for Reversibility of Defective Counterregulation in a Patient with Insulinoma** *A. Maran, J. Taylor, I. A. Macdonald, S. A. Amiel* 765

ROSTRUM

- The Role of the General Practitioner in Diabetes Care** *I. J. Bennett* 769

LIVING WITH DIABETES

- Description of a Diabetes Support Group: Lessons for Diabetes Caregivers** *E. L. Toth, I. James* 773

LETTERS

- Resistance to Injection: The 1991 RD Lawrence Lecture** *R. Taylor* 779
- Human Insulin and Lipotrophy** *M. D. Page, H. J. Bodansky* 779
- Disposal of Needles and Plastic Syringes** *D. K. Chadha, B. I. Chazan* 779
- Type 1 Diabetes in Riyadh: Seasonal Variation** *H. Salman* 780
- Failure to Detect Autoantibodies to Islet Amyloid Polypeptide in Sera from Type 1 Diabetic Patients** *A. B. Tuck, T. J. Wilkin* 781

DM Diary, 692 • Forthcoming Papers, 694 • Media Review, 782 • 'Diabetes Care' Contents Page, 783



0742-3071(199210)9:8-T



WILEY

A WILEY MEDICAL PUBLICATION

DIMEEV 9(8) 689-784 (1992)

ISSN 0742-3071

Acceptance of Manuscripts on Diskette

Diabetes Care welcomes the submission of manuscripts on computer diskettes beginning with the January 1992 issue. The text stored on diskettes, will be used directly for typesetting, which will improve the efficiency and speed of journal production.

Authors should submit diskettes with the final version of their manuscripts, along with the typed revised manuscript. (Do not send diskettes with the initial submission.) All diskettes must be accompanied by 3 accurate double-spaced paper copies of the manuscript.

Either 3.5 or 5.25-inch diskettes can be used, and any major word processing program is acceptable. Diskettes may be produced on IBM, IBM-compatible, Apple, or Wang computers.

Diskettes must be labeled with the following information: 1) author's name, 2) article title, and 3) software and hardware used. Detailed instructions for diskette preparation and submission appear in the instructions for author's guidelines in the first issue of every volume.

**Do you have a
position to fill
or a meeting
to announce
or a product to
sell**

We have the names--

The American Diabetes Association offers you a dynamic market of more than 12,000 health professionals dedicated to improving the standards of treatment for diabetic patients, and to finding a preventive and cure for diabetes

**Call 1-800-232-3472 x 312
today to find out about the
ADA's membership label
rental service--a valuable tool
for direct marketers to reach
over 10,000 professionals who
treat diabetes and related
disorders.**



The facts behind the Glucometer[®] 3 Diabetes Care System with Glucofilm[®] Test Strips

To make the right recommendation about a blood glucose monitoring system demands all the facts on reliability and ease of use. All the facts about the GLUCOMETER[®] 3 Diabetes Care System and GLUCOFILM[®] Test Strips clearly make it the right system for more patients.

Fact: Provides accuracy for professionals, adds simplicity for patients.

A measuring range of 20-500 mg/dL assures you of clinically useful blood glucose results for good diabetes management. One-button operation, easy-to-see display and film-strip accuracy assure patients of simple, yet confident testing. In charts A and B, our data from experienced evaluators and patients with diabetes who tested themselves support high-level accuracy for both groups. The close correlation of GLUCOMETER 3 System values with the Yellow Springs Instrument (YSI) reference method shows this system is right for all.





Fact: GLUCOFILM Test Strips provide the widest hematocrit range available for blood glucose levels from 20-500 mg/dL.

Hematocrit levels from 20% to 60% have shown no significant effect on blood glucose results.

Fact: GLUCOMETER 3 Diabetes Care System is affordable.

Be your own judge of the facts behind this reliable, easy-to-use and affordable blood glucose monitoring system. Contact your Miles Inc., Diagnostics Division representative or write us.




Miles Inc.
Diagnostics Division
P.O. Box 70
Elkhart, IN 46515

The world's leading diabetes experts just wrote the only therapy manual you'll ever need.

Imagine not having to wade through volume after volume of diabetes therapy textbooks that consume too much of your time. Or having the expertise of more than 50 diabetes professionals at your fingertips in one new publication.

Well, the world's leading diabetes experts just wrote the only therapy manual you'll ever need. And it's easy to use!

Therapy for Diabetes Mellitus and Related Disorders has just been published by the American Diabetes Association and is the authoritative guide to diabetes therapy. It's a "how to" reference manual filled with all the information you need to provide the best care for your patients. Yet each of the 49 chapters average just seven pages, so you'll be able to digest the latest in treatment



- Treating diabetic nerve, eye, and kidney disease
- Controlling blood lipid abnormalities in diabetic patients
- Managing diabetic ketoacidosis and hyperglycemic hyperosmolar coma
- Much, much more!

Therapy for Diabetes Mellitus is also filled with more than 170 charts and tables, making each chapter easier to read and understand. Also, the manual's pocket-sized format will allow you to carry it with you for

and therapy in minutes.

You'll learn about:

- The latest drugs for treating diabetes, including sulfonylureas, metformin, and alpha-glucosidase inhibitors
- Genetic counseling for type I diabetes

quick reference whenever necessary.


So order your copy of *Therapy for Diabetes Mellitus and Related Disorders* today. And put the most comprehensive and easy-to-use therapy manual in your pocket.

Yes!

Please send me _____ copies of *Therapy for Diabetes Mellitus and Related Disorders* at \$22.45 for members or \$24.95 for nonmembers. I will be sure to add shipping and handling using the chart below.

Publication Total \$ _____
 Virginia Residents Add 4.5% sales tax \$ _____
 Orders outside the U.S., please add \$15 for each airmail shipment \$ _____
 Add shipping & handling (use chart) \$ _____
 GRAND TOTAL \$ _____

Up to \$5.00	add \$1.75	\$25.01-\$50.00	add \$5.50
\$5.01-\$10.00	add \$3.00	over \$50.00	add 10% of order
\$10.01-\$25.00	add \$4.50		



Name _____
 Address _____
 City _____ State _____ Zip _____

Send your check or money order payable to:

American Diabetes Association
 1970 Chain Bridge Road
 McLean, VA 22109-0592

PCB9201
 Allow 6-8 weeks for delivery. Add \$3.00 to shipping & handling for each additional shipping address. Foreign orders must be paid in U.S. funds, drawn on a U.S. bank. Prices subject to change without notice.

Everyone knows someone with diabetes.

Fourteen million Americans are living with diabetes.

Unfortunately, more than half do not know they have it because diabetes can strike silently. Many will first learn about diabetes when they are treated for one of its complications – kidney disease, blindness, amputation, heart disease or stroke. Know the early warning signs of frequent urination, unusual




thirst, extreme hunger, frequent infections or blurred vision. While there is no cure for diabetes, every day research brings hope. The American Diabetes Association is the nation's leader in the fight against diabetes – funding research, education and patient services.

14 million reasons to find a cure.



Until there's a cure, there's the American Diabetes Association.



More Than 7 Million People Don't Even Know They Have Diabetes.

—Diabetes: 1991 Vital Statistics, pg. 1

You'll find hundreds of timely and vital diabetes statistics like this in ADA's latest fact-filled publication.

Almost every imaginable statistic on diabetes has been gathered for you by ADA and published under one brand new title—*Diabetes: 1991 Vital Statistics*.

Designed as a quick reference manual, *Diabetes: 1991 Vital Statistics* is filled with more than 30 easy-to-read charts and graphs that highlight the latest diabetes statistics. Examples include:

- More than 725,000 new cases of diabetes are diagnosed each year.
- Mexican Americans are three times as likely to develop NIDDM as whites.
- The prevalence of NIDDM is 60 percent higher in blacks than in whites.
- Much more!

There's also a convenient bibliography of tables and figures at the back of the book. It's a great

time-saver when you need to make a quick statistical reference.

Diabetes: 1991 Vital Statistics also contains page after page of information to help you diagnose diabetes and treat and prevent complications. Informative topics include:

- How Diabetes is Diagnosed
- Risk Factors for Diabetes
- Diabetes Complications
- Diabetes Treatment and Prevention
- Much more!

Diabetes: 1991 Vital Statistics provides the latest diabetes statistics and important treatment information. It's sure to be a valuable addition to your personal library.

So order your copy of *Diabetes: 1991 Vital Statistics* today. And become the source for the most timely diabetes information available.

Yes! Please send me _____ copies of *Diabetes: 1991 Vital Statistics* at \$6.25 per copy for members or \$6.95 per copy for nonmembers. I will be sure to add shipping and handling using the chart below.

Publication Total \$ _____
 Virginia Residents Add 4.5% sales tax \$ _____
 Orders outside the U.S., please
 add \$15 for each airmail shipment \$ _____
 Add shipping & handling (use chart) \$ _____
 GRAND TOTAL \$ _____

Shipping & Handling Chart	
Up to \$5.00 add \$1.75	\$25.01-\$50.00 add \$5.50
\$5.01-\$10.00 add \$3.00	over \$50.00 add 10% of order
\$10.01-\$25.00 add \$4.50	



Name _____
 Address _____
 City _____ State _____ Zip _____


Send your check or money order payable to:

American Diabetes Association®
 1970 Chain Bridge Road
 McLean, VA 22109-0592

PCB9202

Allow 6-8 weeks for delivery. Add \$3.00 to shipping & handling for each additional shipping address. Foreign orders must be paid in U.S. funds, drawn on a U.S. bank. Prices subject to change without notice.


Lead a diabetes support group with the newest resource from the American Diabetes Association.



This complete guide for health-care professionals presents a step-by-step approach to planning and conducting support groups for young adults with type I diabetes. Session plans cover everything from recruitment and screening of participants to the final wrap-up and group evaluation. This manual also provides questionnaires, exercises, and fact sheets for use as handouts to participants.

The following topics are covered:

- Managing Sick Days
- Insulin and Insulin Injection Techniques
- Sexuality and Pregnancy
- Aerobic Exercise
- Managing Stress
- Insulin Reactions
- Psychological Issues
- Complications
- New Developments
- Alcohol and Diabetes
- Employment Discrimination and Other Legal Issues



Diabetes Support Groups for Young Adults: A Facilitator's Manual

I would like to order the newest resource from the American Diabetes Association. Please send me:

copies of *Diabetes Support Groups for Young Adults: A Facilitator's Manual*. #PEDSGYA
 ADA Members: \$14.80, Nonmembers: \$16.45 \$ _____
 SUBTOTAL (VA residents add 4.5% state sales tax) \$ _____
 Add Shipping & Handling (see chart) \$ _____
TOTAL \$ _____

NAME _____
 ADDRESS _____
 CITY _____ STATE _____ ZIP _____


Make your check or money order payable to: American Diabetes Association. Mail to: American Diabetes Association, 1970 Chain Bridge Road, McLean, VA 22109-0592.

Shipping & Handling Chart

(calculate using the total cost of publications)

up to \$5.00	\$1.75
\$5.01-\$10.00	\$3.00
\$10.01-\$25.00	\$4.50
\$25.01-\$50.00	\$5.50
over \$50.00	10% of order

Allow 6-8 weeks for domestic delivery. Add \$3.00 to shipping & handling for each additional "ship to" address. Add \$15.00 to shipping & handling for air shipped orders outside the U.S. Prices subject to change without notice.




HURRY! Order your copy today.

All The Recommendation We Think You Need.

“These manuals contain concepts that are essential to the education of every person who undertakes the care of persons with diabetes mellitus. They are highly recommended for medical students, resident physicians, and nurse clinicians.”

Roger W. Turkington, MD
Book Review, JAMA, May 26, 1989
Vol. 20, p. 3037, Copyright 1989



Physician's Guide to
Insulin-Dependent
(Type I) Diabetes
Diagnosis and
Treatment

Physician's Guide to
Non-Insulin-Dependent
(Type II) Diabetes
Diagnosis and
Treatment
Second Edition



Color slide programs, designed to follow the *Guides*, are available for group presentations. Presenter's scripts are included.

Authoritative Resources from the American Diabetes Association.

I am an ADA member and want to take advantage of my member discount.
My Membership Number is _____
(See mailing label on *Diabetes Forecast*)

Please send me

- copies, **Physician's Guide to IDDM** #PTIPG
ADA Members: \$17.95; Nonmembers: \$19.95 \$ _____
- sets, **IDDM Slide Presentation** #PTISS. ADA
Members: \$81.00; Nonmembers: \$90.00 \$ _____
- copies, **Physician's Guide to NIDDM** #PTIIPG.
ADA Members: \$17.95; Nonmembers: \$19.95 \$ _____
- sets, **NIDDM Slide Presentation** #PTIIS.
ADA Members: \$81.00; Nonmembers: \$90.00 \$ _____

Publications Subtotal \$ _____
member discount.
My Membership Number is _____
(See mailing label on *Diabetes Forecast*)

Please send me

- copies, **Physician's Guide to IDDM** #PTIPG
ADA Members: \$17.95; Nonmembers: \$19.95 \$ _____

Name _____
Address _____
City _____
State _____ Zip _____
PCB9204

Shipping & Handling Chart (calculate using publications subtotal)

up to \$5.00	\$1.75	\$25.01-\$50.00	\$5.50
\$5.01-\$10.00	\$3.00	over \$50.00	10% of order
\$10.01-\$25.00	\$4.50		

To order, send your check or money order payable to the American Diabetes Association, 1970 Chain Bridge Road, McLean, VA 22109-0592. Please allow 6-8 weeks for domestic delivery. Add \$3.00

Name _____
Address _____
City _____
State _____

Zip _____
PCB9204

Shipping & Handling Chart

THEY WERE CAREFREE...

They were raised in a simpler time, before sugar-free and fat-free. Now hypertension, often with elevated cholesterol and blood sugar, enters the picture...



NOW THEY'RE CONCERNED...

Today's hypertensives with new concerns...

THE CARDURA



*Adapted from the interim (12 months) results of the Treatment of Mild Hypertension Study, a randomized, double-blind, placebo-controlled trial of a nutritional-hygienic regimen along with various drug therapies. All drugs (except acebutolol) were given initially in low doses. If the patient showed a diastolic blood pressure more than 95 mm Hg on three successive follow-up visits, the dosage was doubled. If blood pressure remained elevated, a second drug (chlorthalidone, except for chlorthalidone group, which was given enalapril) was added. Mean diastolic blood pressure was lowered in the various drug groups with median dosages, as follows: doxazosin (2 mg/day), 12.0 mm Hg; enalapril (5 mg/day), 12.2 mm Hg; chlorthalidone (15 mg/day), 13.1 mm Hg; and acebutolol (400 mg/day), 13.7 mm Hg (n=847; $P<0.01$ vs placebo).

[†]n=128; $P<0.01$ vs placebo. In a pooled analysis of placebo-controlled studies with about 300 predominantly normocholesterolemic patients per treatment group, CARDURA produced a small decrease in total cholesterol (-2.7%) and LDL cholesterol (-4.3%) and a small increase in the HDL/total cholesterol ratio (+4.3%).

[‡]Adapted from Lehtonen et al^{††} (n=77; after 26 weeks: $P<0.001$ compared with week 0 for blood pressure and insulin, $P<0.05$ compared with week 0 for glucose).

GENERATION

Choose **CARDURA**: first-line therapy for a new generation of hypertensives.

Choose CARDURA for blood pressure control that doesn't jeopardize blood lipids.

In the Treatment of Mild Hypertension Study, CARDURA lowered diastolic blood pressure (mean 12.0 mm Hg) as effectively as enalapril, chlorthalidone, and acebutolol[†]

CARDURA lowered blood pressure with a small increase in the HDL/total cholesterol ratio (+2.4%)^{*} in the same study.^{††} The clinical significance of these changes is uncertain. Cholesterol is just one parameter to consider when selecting the best individualized therapy for a given patient

Choose CARDURA for blood pressure control that doesn't compromise blood sugar.

CARDURA controlled diastolic blood pressure without an adverse effect on glucose tolerance or insulin control^{‡‡}

CARDURA is well tolerated. In placebo-controlled studies, only three common side effects were reported significantly more often than placebo: dizziness, somnolence, and fatigue.[§]

Only 2% of patients discontinued therapy due to adverse effects—the same as with placebo

† These were generally mild and transient. Syncope has been reported, but rarely (<1%).

ONCE-A-DAY

CARDURA[®]



(doxazosin mesylate) Scored Tablets
1 mg, 2 mg, 4 mg, 8 mg

HYPERTENSION CONTROL FOR A NEW GENERATION.

Please see brief summary on last page.

©1992, Pfizer Inc

CARDURA[®] (doxazosin mesylate) Tablets
Brief Summary of Prescribing Information
INDICATIONS AND USAGE

CARDURA (doxazosin mesylate) is indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics or beta-adrenergic blocking agents. There is limited experience with CARDURA in combination with angiotensin converting enzyme inhibitors or calcium channel blockers.

CONTRAINDICATIONS

CARDURA is contraindicated in patients with a known sensitivity to quinazolines (e.g. prazosin, terazosin).

WARNINGS

Syncope and "First-dose" Effect:

Doxazosin, like other alpha-adrenergic blocking agents, can cause marked hypotension, especially in the upright position, with syncope and other postural symptoms such as dizziness. Marked orthostatic effects are most common with the first dose but can also occur when there is a dosage increase, or if therapy is interrupted for more than a few days. To decrease the likelihood of excessive hypotension and syncope, it is essential that treatment be initiated with the 1 mg dose. The 2, 4, and 8 mg tablets are not for initial therapy. Dosage should then be adjusted slowly (see DOSAGE AND ADMINISTRATION section) with increases in dose every two weeks. Additional antihypertensive agents should be added with caution.

Patients being treated with doxazosin should be cautioned to avoid situations where injury could result should syncope occur.

In an early investigational study of the safety and tolerance of increasing daily doses of doxazosin in normotensives beginning at 1 mg/day, only 2 of 6 subjects could tolerate more than 2 mg/day without experiencing symptomatic postural hypotension. In another study of 24 healthy normotensive male subjects receiving initial doses of 2 mg/day of doxazosin, seven (29%) of the subjects experienced symptomatic postural hypotension between 0.5 and 6 hours after the first dose necessitating termination of the study. In this study of 2 of the normotensive subjects experienced syncope. Subsequent trials in hypertensive patients always began doxazosin dosing at 1 mg/day resulting in a 4% incidence of postural side effects at 1 mg/day with no cases of syncope.

In multiple dose clinical trials involving over 1500 patients with dose titration every one to two weeks, syncope was reported in 0.7% of patients. None of these events occurred at the starting dose of 1 mg and 1.2% (8/664) occurred at 16 mg/day.

If syncope occurs, the patient should be placed in a recumbent position and treated supportively as necessary.

PRECAUTIONS

General

1. Orthostatic Hypotension:

While syncope is the most severe orthostatic effect of CARDURA, other symptoms of lowered blood pressure, such as dizziness, lightheadedness, or vertigo, can occur, especially at initiation of therapy or at the time of dose increases. These were common in clinical trials, occurring in up to 23% of all patients treated and causing discontinuation of therapy in about 2%.

In placebo controlled titration trials orthostatic effects were minimized by beginning therapy at 1 mg per day and titrating every two weeks to 2, 4, or 8 mg per day. There was an increased frequency of orthostatic effects in patients given 8 mg or more, 10%, compared to 5% at 1-4 mg and 3% in the placebo group.

Patients in occupations in which orthostatic hypotension could be dangerous should be treated with particular caution.

If hypotension occurs, the patient should be placed in the supine position and, if this measure is inadequate, volume expansion with intravenous fluids or vasopressor therapy may be used. A transient hypotensive response is not a contraindication to further doses of CARDURA.

2. Impaired liver function:

CARDURA should be administered with caution to patients with evidence of impaired hepatic function or to patients receiving drugs known to influence hepatic metabolism (see CLINICAL PHARMACOLOGY). There is no controlled clinical experience with CARDURA in patients with these conditions.

3. Leukopenia/Neutropenia:

Analysis of hematologic data from patients receiving CARDURA in controlled clinical trials showed that the mean WBC (N=474) and mean neutrophil counts (N=419) were decreased by 2.4% and 1.0% respectively, compared to placebo, a phenomenon seen with other alpha blocking drugs. A search through a data base of 2400 patients revealed 4 in which drug-related neutropenia could not be ruled out. Two had a single low value on the last day of treatment. Two had stable, non-progressive neutrophil counts in the 1000/mm³ range over periods of 20 and 40 weeks. In cases where follow-up was available the WBCs and neutrophil counts returned to normal after discontinuation of CARDURA. No patients became symptomatic as a result of the low WBC or neutrophil counts.

Information for Patients:

Patients should be made aware of the possibility of syncope and orthostatic symptoms, especially at the initiation of therapy, and urged to avoid driving or hazardous tasks for 24 hours after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed. They should be cautioned to avoid situations where injury could result should syncope occur during initiation of doxazosin therapy. They should also be advised of the need to sit or lie down when symptoms of lowered blood pressure occur, although these symptoms are not always orthostatic, and to be careful when rising from a sitting or lying position. If dizziness, lightheadedness, or palpitations are bothersome they should be reported to the physician, so that dose adjustment can be considered. Patients should also be told that drowsiness or somnolence can occur with doxazosin, requiring caution in people who must drive or operate heavy machinery.

Drug Interactions:

Most (98%) of plasma doxazosin is protein bound. *In vitro* data in human plasma indicate that CARDURA has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin. There is no information on the effect of other highly plasma protein bound drugs on doxazosin binding. CARDURA has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta blocking agents, and nonsteroidal anti-inflammatory drugs.

Drug/Laboratory test interactions:

None known.

Cardiac Toxicity in Animals:

An increased incidence of myocardial necrosis or fibrosis was displayed by Sprague-Dawley rats after 6 months of dietary administration at concentrations calculated to provide 80 mg doxazosin/kg/day and after 12 months of dietary administration at concentrations calculated to provide 40 mg doxazosin/kg/day (150 times the maximum recommended human dose assuming a patient weight of 60 kg). Myocardial fibrosis was observed in both rats and mice treated in the same manner with 40 mg

doxazosin/kg/day for 18 months. No cardiotoxicity was observed at lower doses (up to 10 or 20 mg/kg/day, depending on the study) in either species. These lesions were not observed after 12 months of oral dosing in dogs and Wistar rats at maximum doses of 20 mg/kg/day and 100 mg/kg/day, respectively. There is no evidence that similar lesions occur in humans.

Carcinogenesis, Mutagenesis and Impairment of Fertility:

Chronic dietary administration (up to 24 months) of doxazosin mesylate at maximally tolerated concentrations (highest dose 40 mg/kg; about 150 times the maximum recommended human dose of 16 mg/60 kg) revealed no evidence of carcinogenicity in rats. There was also no evidence of carcinogenicity in a similarly conducted study (up to 18 months of dietary administration) in mice. The mouse study, however, was compromised by the failure to use a maximally tolerated dose of doxazosin.

Mutagenicity studies revealed no drug- or metabolite-related effects at either chromosomal or subchromosomal levels.

Studies in rats showed reduced fertility in males treated with doxazosin at oral doses of 20 (but not 5 or 10) mg/kg/day, about 75 times the maximum recommended human dose. This effect was reversible within two weeks of drug withdrawal.

Pregnancy

Teratogenic Effects, Pregnancy Category B. Studies in rabbits and rats at daily oral doses of up to 40 and 20 mg/kg, respectively (150 and 75 times the maximum recommended daily dose of 16 mg, assuming a patient weight of 60 kg), have revealed no evidence of harm to the fetus. The rabbit study, however, was compromised by the failure to use a maximally tolerated dose of doxazosin. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, CARDURA should be used during pregnancy only if clearly needed.

Radioactivity was found to cross the placenta following oral administration of labelled doxazosin to pregnant rats.

Nonteratogenic Effects. In peri-postnatal studies in rats, postnatal development at maternal doses of 40 or 50 mg/kg/day of doxazosin was delayed as evidenced by slower body weight gain and a slightly later appearance of anatomical features and reflexes.



Nursing Mothers

Studies in lactating rats given a single oral dose of 1 mg/kg of [¹⁴C]-doxazosin indicate that doxazosin accumulates in rat breast milk with a maximum concentration about 20 times greater than the maternal plasma concentration. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CARDURA is administered to a nursing mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

CARDURA has been administered to approximately 4000 patients, of whom 1679 were included in the clinical development program. In that program, minor adverse effects were frequent, but led to discontinuation of treatment in only 7% of patients. In placebo-controlled studies adverse effects occurred in 49% and 40% of patients in the doxazosin and placebo groups, respectively, and led to discontinuation in 2% of patients in each group. The major reasons for discontinuation were postural effects (2%), edema, malaise/fatigue, and some heart rate disturbance, each about 0.7%.

In controlled clinical trials directly comparing CARDURA to placebo there was no significant difference in the incidence of side effects, except for dizziness (including postural), weight gain, somnolence and fatigue/malaise. Postural effects and edema appeared to be dose related.

The prevalence rates presented below are based on combined data from placebo-controlled studies involving once daily administration of doxazosin at doses ranging from 1-16 mg. Table 1 summarizes those adverse experiences (possibly/probably related) reported for patients in these studies where the prevalence rate in the doxazosin group was at least 0.5% or where the reaction is of particular interest.

TABLE 1
ADVERSE REACTIONS DURING PLACEBO CONTROLLED STUDIES

		DOXAZOSIN (N=339)	PLACEBO (N=336)
CARDIOVASCULAR:	Dizziness	19%	9%
	Vertigo	2%	1%
	Postural Hypotension	0.3%	0%
	Edema	4%	3%
	Palpitation	2%	3%
	Arrhythmia	1%	0%
	Hypotension	1%	0%
SKIN APPENDAGES:	Tachycardia	0.3%	1%
	Peripheral Ischemia	0.3%	0%
	Rash	1%	1%
	Pruritus	1%	1%

References: 1. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study: a randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. *Arch Intern Med* 1991;151:1413-1423. 2. Lehtonen A, the Finnish Multicenter Study Group. Lowered levels of serum insulin, glucose, and cholesterol in hypertensive patients during treatment with doxazosin. *Curr Ther Res* 1990;47:278-284.

	DOXAZOSIN (N=339)	PLACEBO (N=336)	
MUSCULOSKELETAL:	Arthralgia/Arthritis	1%	0%
	Muscle Weakness	1%	0%
	Myalgia	1%	0%
CENTRAL & PERIPHERAL N.S.:	Headache	14%	16%
	Paresthesia	1%	1%
	Kinetic Disorders	1%	0%
	Ataxia	1%	0%
	Hypertonia Muscle Cramps	1%	0%
AUTONOMIC:	Mouth Dry	2%	2%
	Flushing	1%	0%
SPECIAL SENSES:	Vision Abnormal	2%	1%
	Conjunctivitis/Eye Pain	1%	1%
	Tinnitus	1%	0.3%
PSYCHIATRIC:	Somnolence	5%	1%
	Nervousness	2%	2%
	Depression	1%	1%
	Insomnia	1%	1%
	Sexual Dysfunction	2%	1%
GASTROINTESTINAL:	Nausea	3%	4%
	Diarrhea	2%	3%
	Constipation	1%	1%
	Dyspepsia	1%	1%
	Flatulence	1%	1%
	Abdominal Pain Vomiting	0%	2%
RESPIRATORY:	Rhinitis	3%	1%
	Dyspnea	1%	1%
	Epistaxis	1%	0%
URINARY:	Polyuria	2%	0%
	Urinary Incontinence	1%	0%
	Micturition Frequency	0%	2%
GENERAL:	Fatigue/Malaise	12%	6%
	Chest Pain	2%	2%
	Asthenia	1%	1%
	Face Edema	1%	0%
	Pain	2%	2%

Additional adverse reactions have been reported, but these are, in general, not distinguishable from symptoms that might have occurred in the absence of exposure to doxazosin. The following adverse reactions occurred with a frequency of between 0.5% and 1%: syncope, hyposthesia, increased sweating, agitation, increased weight. The following additional adverse reactions were reported by <0.5% of 3960 patients who received doxazosin in controlled or open, short- or long-term clinical studies, including international studies. **Cardiovascular System:** angina pectoris, myocardial infarction, cerebrovascular accident; **Autonomic Nervous System:** pallor; **Metabolic:** thirst, gout, hypokalemia; **Hematopoietic:** lymphadenopathy, purpura; **Reproductive System:** breast pain; **Skin Disorders:** alopecia, dry skin, eczema; **Central Nervous System:** paresis, tremor, twitching, confusion, migraine, impaired concentration; **Psychiatric:** paranoia, amnesia, emotional lability, abnormal thinking, depersonalization; **Special Senses:** parosmia, earache, taste perversion, photophobia, abnormal lacrimation; **Gastrointestinal System:** increased appetite, anorexia, fecal incontinence, gastroenteritis; **Respiratory System:** bronchospasm, sinusitis, coughing, pharyngitis; **Urinary System:** renal calculus; **General Body System:** hot flushes, back pain, infection, fever/rigors, decreased weight, influenza-like symptoms.

CARDURA has not been associated with any clinically significant changes in routine biochemical tests. No clinically relevant adverse effects were noted on serum potassium, serum glucose, uric acid, blood urea nitrogen, creatinine or liver function tests. SERUM GLUCOSE has been associated with decreases in white blood cell counts (See Precautions).

OVERDOSAGE

The oral LD₅₀ of doxazosin is greater than 1000 mg/kg in mice and rats. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of fluid. As doxazosin is highly protein bound, dialysis would not be indicated.

DOSAGE AND ADMINISTRATION

DOSAGE MUST BE INDIVIDUALIZED. The initial dosage of CARDURA in hypertensive patients is 1 mg given once daily. This starting dose is intended to minimize the frequency of postural hypotension and first dose syncope associated with CARDURA. Postural effects are most likely to occur between 2 and 6 hours after a dose. Therefore blood pressure measurements should be taken during this time period after the first dose and with each increase in dose. Depending on the individual patient's standing blood pressure response (based on measurements taken at 2-6 hours postdose and 24 hours postdose), dosage may then be increased to 2 mg and thereafter if necessary to 4 mg, 8 mg and 16 mg to achieve the desired reduction in blood pressure. **Increases in dose beyond 4 mg increase the likelihood of excessive postural effects including syncope, postural dizziness/vertigo, postural hypotension. At a titrated dose of 16 mg once daily the frequency of postural effects is about 12% compared to 3% for placebo.**

HOW SUPPLIED

CARDURA (doxazosin mesylate) is available as colored tablets for oral administration. Each tablet contains doxazosin mesylate equivalent to 1 mg (white), 2 mg (yellow), 4 mg (orange) or 8 mg (green) of the active constituent, doxazosin.

CARDURA TABLETS are available as 1 mg (white), 2 mg (yellow), 4 mg (orange) and 8 mg (green) scored tablets. Bottles of 100: 1 mg (NDC 0049-2750-66), 2 mg (NDC 0049-2760-66), 4 mg (NDC 0049-2770-66), 8 mg (NDC 0049-2780-66). Recommended Storage: Store below 86°F (30°C).


CAUTION: Federal law prohibits dispensing without prescription. 65-4538-00-0 Issued Nov 1990



Right foot, plantar
surface of a 45-year-old
male with diabetes.

Week one

A complete treatment program for chronic wounds



Week eleven

Only the Wound Care Center® offers a comprehensive outpatient wound management program provided by an expert team of physicians, nurses, and technicians. Located in select hospitals, each center provides a treatment program that includes:

- wound assessment and classification
- vascular studies
- infection control
- aggressive debridement
- autologous growth factor therapy
- protective devices
- patient education

When you refer your patient to the Wound Care Center you will remain an active member of your patient's health management team. As an adjunctive therapeutic service, the Wound Care Center assists in your total wound management.

Wound Care Center®

For your patients with wounds that won't heal.

To refer a patient or obtain further information about the Wound Care Center nearest you, return the attached reply card.



Wound Care Center® is a registered trademark of Curative Technologies, Inc., Setauket, NY. Wound Care Centers are owned/operated by select hospitals affiliated with Curative Technologies, Inc.

Copyright © 1992, Curative Technologies, Inc. All rights reserved.

4/92 4001

From the Next Generation of rDNA Technology

NOVOLIN[®] 70/30



Combining Control and Confidence

When it comes to glycemic CONTROL, the ideal insulin response is a natural one. NOVOLIN[®] 70/30 has been formulated to provide rapid onset with sustained duration for a more natural insulin profile than NPH alone.



When it comes to CONFIDENCE, you look for safety, accuracy, and convenience.

NOVOLIN[®] 70/30 eliminates measuring and mixing errors and may improve patient adherence through a simple B.I.D. dosing regimen.

NOVOLIN[®] 70/30

Human Insulin
(recombinant DNA origin)

Combining Control and Confidence

For more information, call 1-800-727-6500.

WARNING: ANY CHANGE IN INSULIN SHOULD BE MADE CAUTIOUSLY AND ONLY UNDER MEDICAL SUPERVISION.